Alaunos Therapeutics (TCRT) 10-K 2 Mar 20 2019 FY Annual report Financial data

Cover Page

Cover Page - USD ($)	12 Months Ended
	Dec. 31, 2019	Feb. 14, 2020	Jun. 28, 2019
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	FY
Entity Registrant Name	ZIOPHARM ONCOLOGY INC
Entity Central Index Key	0001107421
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Trading Symbol	ZIOP
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Public Float			$ 834,869,811
Entity Common Stock, Shares Outstanding		212,999,979
Entity Interactive Data Current	Yes
Title of 12(b) Security	Common Stock
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity Address, State or Province	MA

BALANCE SHEETS

BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 79,741	$ 61,729
Receivables	3,330	1,864
Prepaid expenses and other current assets	22,421	20,692
Total current assets	105,492	84,285
Property and equipment, net	1,110	1,097
Deposits	130	128
Right-of-use asset	2,272
Other non-current assets	110	9,541
Total assets	109,114	95,051
Current liabilities:
Accounts payable	906	707
Accrued expenses	10,846	8,763
Lease liability - current portion	774
Deferred rent - current portion		13
Total current liabilities	12,526	9,483
Lease liability - noncurrent portion	1,578
Deferred rent - noncurrent portion		4
Total liabilities	14,104	9,487
Commitments and contingencies (Note 9)
Preferred stock, $0.001 par value, 30,000,000 shares authorized
Stockholders' equity:
Common stock, $0.001 par value; 250,000,000 shares authorized; 181,803,320 and 161,066,136 shares issued and outstanding at December 31, 2019 and 2018, respectively	182	161
Additional paid-in capital	778,953	651,732
Accumulated deficit	(684,125)	(566,329)
Total stockholders' equity	95,010	85,564
Total liabilities and stockholders' equity	109,114	$ 95,051
Series 1 Preferred Stock
Current liabilities:
Series 1 preferred stock, $1,200 stated value; 250,000 designated; 0 shares issued and outstanding at December 31, 2019 and 2018; liquidation value of $0 million at December 31, 2019 and 2018

BALANCE SHEETS (Parenthetical)

BALANCE SHEETS (Parenthetical) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	30,000,000	30,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	181,803,320	161,066,136
Common stock, shares outstanding	181,803,320	161,066,136
Series 1 Preferred Stock
Preferred stock, stated value	$ 1,200	$ 1,200
Preferred stock, shares authorized	250,000	250,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Preferred stock, liquidation preference	$ 0	$ 0

STATEMENTS OF OPERATIONS

STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Statement [Abstract]
Collaboration revenue		$ 146	$ 6,389
Operating expenses:
Research and development	$ 38,331	34,134	45,084
General and administrative	19,527	19,918	14,798
Total operating expenses	57,858	54,052	59,882
Loss from operations	(57,858)	(53,906)	(53,493)
Other income, net	813	631	465
Non-cash inducement warrant expense	(60,751)
Change in fair value of derivative liabilities	0	158	(1,295)
Net loss	(117,796)	(53,117)	(54,323)
Preferred stock dividends		(16,998)	(18,938)
Settlement of a related party relationship		207,361
Net income (loss) applicable to common stockholders	$ (117,796)	$ 137,246	$ (73,261)
Net income (loss) per share - basic	$ (0.70)	$ 0.96	$ (0.53)
Net income (loss) per share - diluted	$ (0.70)	$ 0.96	$ (0.53)
Weighted average common shares outstanding used to compute basic net income (loss) per share	167,952,114	143,508,674	136,938,264
Weighted average common shares outstanding used to compute diluted net income (loss) per share	167,952,114	143,710,160	136,938,264

STATEMENTS OF CHANGES IN PREFER

STATEMENTS OF CHANGES IN PREFERRED STOCK AND STOCKHOLDERS' Equity (DEFICIT) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid In Capital Common Stock	Accumulated Deficit	Series 1 Preferred Stock - Mezzanine
Balance at Dec. 31, 2016	$ (77,298)	$ 132	$ 580,567	$ (657,997)	$ 125,321
Balance (in shares) at Dec. 31, 2016		132,376,670			106,184
Adjustment for implementation of ASU No. 2014-09, Revenue from Contracts with Customers			122	(122)
Stock-based compensation	8,454		8,454
Issuance of restricted common stock		$ 1	(1)
Issuance of restricted common stock (in shares)		907,032
Exercise of employee stock options	$ 88	$ 1	87
Exercise of employee stock options (in shares)	180,000	59,864
Repurchase of restricted common stock	$ (2,059)	$ (1)	(2,058)
Repurchase of restricted common stock (Shares)		(394,267)
Issuance of common stock in connection with at the market offering, net	47,270	$ 10	47,260
Issuance of common stock in connection with at the market offering, net (in shares)		9,708,738
Preferred stock dividends					$ 18,672
Preferred stock dividends	(18,938)		(18,938)
Preferred stock dividends (in shares)					13,460
Net loss	(54,323)			(54,323)
Balance at Dec. 31, 2017	(96,806)	$ 143	615,493	(712,442)	$ 143,993
Balance (in shares) at Dec. 31, 2017		142,658,037			119,644
Adjustment for implementation of ASU No. 2014-09, Revenue from Contracts with Customers	(8,131)			(8,131)
Stock-based compensation	7,534		7,534
Issuance of restricted common stock	1	$ 2	(1)
Issuance of restricted common stock (in shares)		150,321
Exercise of employee stock options	$ 242	$ 2	240
Exercise of employee stock options (in shares)	104,167	104,166
Cancelled restricted common stock	$ 1	$ (2)	3
Cancelled restricted common stock (in shares)		(271,433)
Repurchase of restricted common stock	(1,624)	$ (3)	(1,621)
Repurchase of restricted common stock (Shares)		(514,349)
Issuance of common stock in connection with at the market offering, net	47,101	$ 19	47,082
Issuance of common stock in connection with at the market offering, net (in shares)		18,939,394
Preferred stock dividends					$ 16,775
Preferred stock dividends	(16,998)		(16,998)
Preferred stock dividends (in shares)					11,415
Settlement of a related party relationship (Note 7)	207,361			207,361	$ (160,767)
Settlement of a related party relationship (Note 7) (in shares)					(131,059)
Net loss	(53,117)			(53,117)
Balance at Dec. 31, 2018	85,564	$ 161	651,732	(566,329)
Balance (in shares) at Dec. 31, 2018		161,066,136
Stock-based compensation	6,341		6,341
Issuance of restricted common stock	1,000	$ 2	998
Issuance of restricted common stock (in shares)		1,519,766
Exercise of employee stock options	$ 1,219		1,219
Exercise of employee stock options (in shares)	581,105	443,051
Cancelled restricted common stock (in shares)		(74,599)
Issuance of common stock upon exercise of warrants, net	$ 60,751		60,751
Repurchase of restricted common stock	(653)		(653)
Repurchase of restricted common stock (Shares)		(225,339)
Issuance of common stock in connection with at the market offering, net	$ 6,085	$ 1	6,084
Issuance of common stock in connection with at the market offering, net (in shares)	2,814,673	1,271,274
Warrant exercise, net of commissions and expenses of $1.1 million	$ 52,499	$ 18	52,481
Warrant exercise, net of commissions and expenses of $1.1 million (in shares)		17,803,031
Net loss	(117,796)			(117,796)
Balance at Dec. 31, 2019	$ 95,010	$ 182	$ 778,953	$ (684,125)
Balance (in shares) at Dec. 31, 2019		181,803,320

STATEMENTS OF CHANGES IN PREF_2

STATEMENTS OF CHANGES IN PREFERRED STOCK AND STOCKHOLDERS' Equity (DEFICIT) (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Issuance of common stock, commissions and expenses		$ 2,898	$ 2,700
Common stock issuance cost		$ 2,898	$ 2,700
Market Offering [Member]
Issuance of common stock, commissions and expenses	$ 100
Common stock issuance cost	100
Warrant [Member]
Issuance of common stock, commissions and expenses	1,100
Common stock issuance cost	$ 1,100

STATEMENTS OF CASH FLOWS

STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Cash flows from operating activities:
Net loss	$ (117,796)	$ (53,117)	$ (54,323)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	629	575	369
Stock-based compensation	7,341	7,534	8,454
Non-cash inducement warrant expense	60,751
Change in fair value of derivative liabilities	0	(158)	1,295
(Increase) decrease in:
Receivables	(1,466)	(1,845)	2
Prepaid expenses and other current assets	(1,729)	(1,263)	3,992
Deposits	(2)
Other noncurrent assets	9,431	3,942	(12,991)
Increase (decrease) in:
Accounts payable	199	(3,709)	4,261
Accrued expenses	1,725	(1,145)	800
Deferred revenue		(146)	(6,389)
Deferred rent	0	(125)	(139)
Lease liabilities	63
Net cash used in operating activities	(40,854)	(49,457)	(54,669)
Cash flows from investing activities:
Purchases of property and equipment	(284)	(459)	(737)
Net cash used in investing activities	(284)	(459)	(737)
Cash flows from financing activities:
Proceeds from exercise of stock options	1,219	240	88
Issuance of restricted common stock			(2,059)
Repurchase of common stock	(653)	(1,622)	0
Proceeds from issuance of common stock, net			47,270
Proceeds from underwritten financing		47,101
Issuance of common stock upon exercise of warrants, net	52,499
Issuance of common stock in connection with an at the market offering, net	6,085
Cash paid for settlement of related party relationship		(5,408)
Net cash provided by financing activities	59,150	40,311	45,299
Net decrease in cash and cash equivalents, and restricted cash	18,012	(9,605)	(10,107)
Cash and cash equivalents, and restricted cash, beginning of period	61,729	71,334	81,441
Cash and cash equivalents, and restricted cash, end of period	79,741	61,729	71,334
Supplementary disclosure of cash flow information:
Bonus paid in common stock	1,000
Fixed assets in accrued expenses	$ 358
Supplementary disclosure of noncash investing and financing activities:
Noncash portion of related party relationship settlement		212,769
Series 1 Preferred Stock
Supplementary disclosure of noncash investing and financing activities:
Payment of dividends in preferred stock		$ 16,998	$ 18,938

Organization

Organization	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Organization	1. Organization ZIOPHARM Oncology, Inc., which is referred to herein as “ZIOPHARM,” or the “Company,” is a biopharmaceutical company seeking to develop, acquire, and commercialize, on its own or with partners, a diverse portfolio of immuno-oncology therapies. The Company’s operations to date have consisted primarily of raising capital and conducting research and development. The Company’s fiscal year ends on December 31. The Company has operated at a loss since its inception in 2003 and has no recurring revenues from operations. The Company anticipates that losses will continue for the foreseeable future. As of December 31, 2019, the Company has approximately $79.7 million of cash and cash equivalents, in addition to an aggregate of approximately $98.0 million of net proceeds that the Company raised in January and February 2020 from an underwritten public offering and its at-the-market mid-2022,

Financings

Financings	12 Months Ended
	Dec. 31, 2019
Text Block [Abstract]
Financings	2. Financings February 2020 Public Offering On February 5, 2020, the Company entered into an underwriting agreement with Jefferies, as representative of the several underwriters named therein, relating to the issuance and sale of 27,826,086 shares of its common stock. The price to the public in the offering was $3.25 per share, and the underwriters agreed to purchase the shares from the Company pursuant to the underwriting agreement at a purchase price of $3.055 per share. Under the terms of the underwriting agreement, the Company also granted the underwriters an option, exercisable for 30 days, to purchase up to an additional 4,173,912 shares of common stock at a purchase price of $3.055 per share. The offering was made pursuant to the Company’s effective registration statement on Form S-3ASR No. 333-232283) At-the-Market Subsequent to De cember 31, 2019 S-3ASR File During the year ended December 31, 2019, the Company sold an aggregate of 1,271,274 shares of its common stock. The offering was made pursuant to the Company’s effective registration statement on Form S-3ASR File November 2018 Private Placement and 2019 Inducement Warrants On November 11, 2018, the Company entered into a securities purchase agreement with certain institutional and accredited investors pursuant to which it sold an aggregate of 18,939,394 immediately separable units at a price per unit of $2.64 to such investors, for net proceeds of approximately $47.1 million. Each unit was comprised of (i) one share of the Company’s S-3 July 2019 and September 2019 Warrant Exercise On July 26, 2019 and September 12, 2019, the Company entered into agreements for the exercise of the warrants issued in November 2018 to purchase common stock in a private placement. Pursuant to the terms of the agreements, investors exercised warrants for an aggregate of 17,803,031 shares of common stock, at an exercise price of $3.01 per share. The Company issued new warrants to purchase up to 17,803,031 additional shares of common stock as an inducement for warrant holders to exercise their 2018 warrants early. The new warrants will become exercisable six months following the date of issuance, will expire on the fifth anniversary of the initial exercise date, and have an exercise price of $7.00 (Note 14). Proceeds from the exercise of the warrants, before deducting placement agent fees and other related expenses of $1.1 million were approximately $52.5 million. For the year ended December 31, 2019, the Company also recorded $60.8 million in non-cash which is included in the Company’s statement of operations. May 2017 Offering On May 11, 2017, the Company sold in an underwritten offering an aggregate of 9,708,738 shares of its common stock to a single investor. The price to the investor in the offering was $5.15 per share, and the underwriters agreed to purchase the shares from the Company pursuant to the underwriting agreement at a purchase price of $4.893 per share. The net proceeds from the offering were approximately $47.3 million after deducting underwriting commissions and estimated offering expenses payable by the Company.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	3. Summary of Significant Accounting Policies Basis of Presentation The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America or U.S. GAAP. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Although the Company regularly assesses these estimates, actual results could differ from those estimates. Changes in estimates are recorded in the period in which they become known. The Company’s most significant estimates and judgments used in the preparation of the financial statements are: • Clinical trial expenses; • Collaboration agreements; • Fair value measurements of stock-based compensation and Series 1 preferred stock (and related dividends); and • Income taxes. Subsequent Events The Company evaluated all events and transactions that occurred after the balance sheet date through the date of this filing. Except as disclosed below, the Company did not have any material subsequent events that impacted its financial statements or disclosures. February 2020 Public Offering On February 5, 2020, the Company entered into an underwriting agreement with Jefferies, as representative of the several underwriters named therein, relating to the issuance and sale of 27,826,086 shares of its common stock. The net proceeds from the offering were approximately $85.0 million after deducting underwriting discounts and offering expenses paid by the Company (see Note 2). At-the-Market Subsequent to the balance sheet date, the Company sold an aggregate of 2,814,673 shares of its common stock. The offering was made pursuant to the Company’s effective registration statement on Form S-3ASR Amendment - License Agreement with the National Cancer Institute On January 8, 2020, we amended the Patent License to expand the TCR library licensed from the NCI to include additional TCRs reactive to mutated KRAS and TP53 neoantigens. Under the amendment to the patent license, we agreed to pay the NCI a cash payment of $600,000 within sixty days of the amendment. Cash and Cash Equivalents Cash equivalents consist primarily of demand deposit accounts and deposits in short-term U.S. treasury money market mutual funds. Cash equivalents are stated at cost, which approximates fair market value. The following table provides a reconciliation of cash, cash equivalents, and restricted cash within the statement of financial position that sum to the total of the same such amounts shown in the statement of cash flows. December 31, (in thousands) 2019 2018 2017 Cash and cash equivalents $ 79,741 $ 61,729 $ 70,946 Restricted cash included in prepaid expenses and other current assets — — 388 Total cash, cash equivalents, and restricted cash shown in the statement of cash flows $ 79,741 $ 61,729 $ 71,334 Concentrations of Credit Risk Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company maintains cash accounts in commercial banks, which may, at times, exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on cash and cash equivalents. Property and Equipment Property and equipment are recorded at cost. Expenditures for maintenance and repairs are charged to expense while the costs of significant improvements are capitalized. Depreciation is provided using the straight-line method over the following estimated useful lives of the related assets, which is between three and five years. Upon retirement or sale, the cost of the assets disposed of and the related accumulated depreciation are eliminated from the balance sheets and related gains or losses are reflected in the statements of operations. Long-Lived Assets The Company reviews the carrying values of its long-lived assets for possible impairment whenever events or changes in circumstances indicate that the carrying amounts of the assets may not be recoverable. Any long-lived assets held for disposal are reported at the lower of their carrying amounts or fair values less costs to sell. Operating Segments Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, the Company’s Chief Executive Officer, in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment and does not track expenses on a program-by-program Warrants The Company assesses whether warrants issued require accounting as derivatives. The Company determined that the warrants were (1) indexed to the Company’s own stock and (2) classified in stockholders’ equity in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 815, Derivatives and Hedging Fair Value Measurements The Company has certain financial assets and liabilities recorded at fair value which have been classified as Level 1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements. • Level 1—Quoted prices in active markets for identical assets or liabilities. • Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. • Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Assets and liabilities measured at fair value on a recurring basis as of December 31, 2019 and 2018 are as follows: ($ in thousands) Fair Value Measurements at Reporting Date Using Description Balance as of Quoted Prices in Significant Other Significant Cash equivalents $ 68,031 $ 68,031 $ — $ — ($ in thousands) Fair Value Measurements at Reporting Date Using Description Balance as of Quoted Prices in Significant Other Significant Cash equivalents $ 24,437 $ 24,437 $ — $ — The cash equivalents represent demand deposit accounts and deposits in a short-term United States treasury money market mutual fund quoted in an active market and classified as a Level 1 asset. Revenue Recognition from Collaboration Agreements The Company adopted Accounting Standards Codification, or ASC Topic 606, Revenue from Contracts with Customers, The Company primarily generates revenue through collaboration arrangements with strategic partners for the development and commercialization of product candidates. Commencing January 1, 2018, the Company recognized revenue in accordance with ASC 606 which replaced ASC 605, Multiple Element Arrangements The Company recognizes collaboration revenue under certain of the Company’s license or collaboration agreements that are within the scope of ASC 606. The Company’s contracts with customers typically include promises related to licenses to intellectual property, research and development services and options to purchase additional goods and/or services. If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, up-front non-refundable, up-front The terms of the Company’s arrangements with customers typically include the payment of one or more of the following: (i) non-refundable, up-front catch-up The Company allocates the transaction price to each performance obligation identified in the contract on a relative standalone selling price basis. However, certain components of variable consideration are allocated specifically to one or more particular performance obligations in a contact to the extent both of the following criteria are met: (i) the terms of the payment relate specifically to the efforts to satisfy the performance obligation or transfer the distinct good or service and (ii) allocating the variable amount of consideration entirely to the performance obligation or the distinct good or service is consistent with the allocation objective of the standard whereby the amount allocated depicts the amount of consideration to which the entity expects to be entitled in exchange for transferring the promised goods or services. The Company develops assumptions that require judgment to determine the standalone selling price for each performance obligation identified in each contract. The key assumptions utilized in determining the standalone selling price for each performance obligation may include forecasted revenues, development timelines, estimated research and development costs, discount rates, likelihood of exercise and probabilities of technical and regulatory success. Revenue is recognized based on the amount of the transaction price that is allocated to each respective performance obligation when or as the performance obligation is satisfied by transferring a promised good and/or service to the customer. For performance obligations that are satisfied over time, the Company recognizes revenue by measuring the progress toward complete satisfaction of the performance obligation using a single method of measuring progress which depicts the performance in transferring control of the associated goods and/or services to the customer. The Company uses input methods to measure the progress toward the complete satisfaction of performance obligations satisfied over time. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. Any such adjustments are recorded on a cumulative catch-up T received in 2015 a former w e r e were There were d 340-40, Other Assets and Deferred Costs: Contracts with Customers The Company d id re-evaluate Impact of Topic 606 Adoption As a result of adopting ASC 606, the Company recorded an $8.1 million adjustment to the opening balance of accumulated deficit in the first quarter of 2018 as a result of the treatment of the up-front 605-25 ($ in thousands) Impact of Topic 606 Adoption Description As reported under Adjustments Balances without Contract liability, current portion $ 622 $ (5,767 ) $ 6,389 Contract liability, net of current portion $ 49,037 $ 13,898 $ 35,139 Accumulated deficit $ (720,573 ) $ (8,131 ) $ (712,442 ) ($ in thousands) Impact of Topic 606 Adoption Description As reported under Adjustments Balances without Collaboration revenue $ 146 $ (4,732 ) $ 4,878 Net loss $ (53,117 ) $ (4,732 ) $ (48,385 ) Net income (loss) applicable to common shareholders $ 137,246 $ (4,732 ) $ 141,978 Net income (loss) per share - basic $ 0.96 $ (0.03 ) $ 0.99 Net income (loss) per share - diluted $ 0.96 $ (0.03 ) $ 0.99 ($ in thousands) Impact of Topic 606 Adoption Description As reported under Adjustments Balances without Net loss $ (53,117 ) $ (4,732 ) $ (48,385 ) Changes in contract liability $ — $ — $ — The most significant change above relates to the Company’s collaboration revenue, which to date has been exclusively generated from its collaboration arrangement with Ares Trading and PGEN Therap eutic s , a wholly owned subsidiary of Precigen I nc., or P recigen , w hich was known as I nt rexon C orporation up-front Research and Development Costs Research and development expenditures are charged to the statement of operations as incurred. Such costs include proprietary research and development activities, purchased research and development, and expenses associated with research and development contracts, whether performed by the Company or contracted with independent third parties. Income Taxes Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences of temporary differences between the financial statement carrying amounts and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which the temporary differences are expected to be recovered or settled. The Company evaluates the realizability of its deferred tax assets and establishes a valuation allowance when it is more likely than not that all or a portion of deferred tax assets will not be realized. The Company accounts for uncertain tax positions using a “more-likely-than-not” Accounting for Stock-Based Compensation Stock-based compensation cost is measured at the grant date, based on the estimated fair value of the award, and is recognized as expense over the employee’s requisite service period. Stock-based compensation expense is based on the number of awards ultimately expected to vest and is therefore reduced for an estimate of the awards that are expected to be forfeited prior to vesting. Consistent with prior years, the Company uses the Black-Scholes option pricing model which requires estimates of the expected term option holders will retain their options before exercising them and the estimated volatility of the Company’s common stock price over the expected term. The Company recognizes the full impact of its share-based employee payment plans in the statements of operations for each of the years ended December 31, 2019, 2018, and 2017 and did not capitalize any such costs on the balance sheets. The Company recognized $4.0 million, $3.0 million, and $2.5 million of compensation expense related to stock options during the years ended December 31, 2019, 2018, and 2017, respectively. In the years ended December 31, 2019, 2018, and 2017, the Company recognized $2.3 million, $4.5 million, and $6.0 million of compensation expense, respectively, related to restricted stock (Note 14). The total compensation expense relating to vesting of stock options and restricted stock awards for the years ended December 31, 2019, 2018, and 2017 was $6.3 million, $7.5 million, and $8.5 million, respectively. The following table presents share-based compensation expense included in the Company’s Statements of Operations: Year ended December 31, (in thousands) 2019 2018 2017 Research and development $ 1,461 $ 1,683 $ 2,401 General and administrative 4,880 5,851 6,053 Share based employee compensation expense before tax $ 6,341 $ 7,534 $ 8,454 Income tax benefit — — — Net share based employee compensation expense $ 6,341 $ 7,534 $ 8,454 The fair value of each stock option is estimated at the date of grant using the Black-Scholes option pricing model. The estimated weighted-average fair value of stock options granted to employees in 2019, 2018, and 2017 was approximately $2.47, $1.64, and $3.94 per share, respectively. Assumptions regarding volatility, expected term, dividend yield and risk-free interest rate are required for the Black-Scholes model. The volatility assumption is based on the Company’s historical experience. The risk-free interest rate is based on a U.S. treasury note with a maturity similar to the option award’s expected life. The expected life represents the average period of time that options granted are expected to be outstanding. The Company calculated expected term using the simplified method described in SEC Staff Accounting Bulletin, or SAB, No. 107 and No. 110 as it continues to meet the requirements promulgated in SAB No. 110. The assumptions for volatility, expected life, dividend yield and risk-free interest rate are presented in the table below: 2019 2018 2017 Weighted average risk-free interest rate 1.39 - 2.53% 2.55 - 3.06% 1.85 - 2.27% Expected life in years 5.75 - 6.25 6 6 Expected volatility 71.39 - 85.00% 80.75 - 84.71% 80.31 - 81.03% Expected dividend yield 0 0 0 Net Income ( ) Basic net loss per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding for the period. Diluted earnings (loss) per share is computed using the weighted-average number of common shares outstanding during the period, plus the dilutive effect of outstanding options and warrants, using the treasury stock method and the average market price of the Company’s common stock during the applicable period. For the Year Ended December 31, in thousands, except share and per share data 2019 2018 2017 Basic Net loss $ (117,796 ) $ (53,117 ) $ (54,323 ) Preferred stock dividends — (16,998 ) (18,938 ) Settlement of a related party relationship — 207,361 — Net income / (loss) applicable to common shareholders $ (117,796 ) $ 137,246 $ (73,261 ) Weighted-average common shares outstanding 167,952,114 143,508,674 136,938,264 Earnings per share, basic $ (0.70 ) $ 0.96 $ (0.53 ) Diluted Net Loss $ (117,796 ) $ (53,117 ) $ (54,323 ) Preferred stock dividends — (16,998 ) (18,938 ) Precigen license transaction — 207,361 — Net income / (loss) applicable to common shareholders $ (117,796 ) $ 137,246 $ (73,261 ) Weighted-average common shares outstanding 167,952,114 143,508,674 136,938,264 Effect of dilutive securities Stock options — 201,362 — Unvested restricted common stock — 124 — Warrants — — — Dilutive potential common shares — 201,486 — Shares used in calculating diluted earnings per share 167,952,114 143,710,160 136,938,264 Earnings per share, diluted $ (0.70 ) $ 0.96 $ (0.53 ) Certain shares related to some of the Company’s outstanding common stock options, unvested restricted stock, preferred stock, and warrants have not been included in the computation of diluted net earnings (loss) per share for the years ended December 31, 2019, 2018 and 2017 as the result would be antidilutive. Such potential common shares at December 31, 2019, 2018, and 2017 consist of the following: December 31, 2019 2018 2017 Stock options 6,872,879 5,075,723 4,352,135 Unvested restricted stock 939,636 681,946 1,808,559 Preferred stock — — 34,134,524 Warrants 22,272,727 18,939,394 — 30,085,242 24,697,063 40,295,218 During the year ended December 31, 2018, the Company and PGEN, entered into a License Agreement to replace all existing agreements between the companies that provides the Company with certain exclusive and non-exclusive New Accounting Pronouncements In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement 2018-03. In June 2018, the FASB issued ASU No. 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting 2018-07. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) right-of-use No. 2016-02, non-lease Leases In May 2017, the FASB issued ASU No. 2017-09, Compensation—Stock Compensation Scope of Modification Accounting 2017-09, 2017-09

Property and Equipment, net

Property and Equipment, net	12 Months Ended
	Dec. 31, 2019
Property, Plant and Equipment [Abstract]
Property and Equipment, net	4. Property and Equipment, net Property and equipment, net, consists of the following: December 31, (in thousands) 2019 2018 Office and computer equipment $ 1,436 $ 1,249 Software 1,030 1,030 Leasehold improvements 1,892 1,839 Research and development equipment 1,195 1,182 Capital in-process 389 — 5,942 5,300 Less: accumulated depreciation (4,832 ) (4,203 ) Property and equipment, net $ 1,110 $ 1,097 Depreciation charged to the statement of operations for the years ended December 31, 2019, 2018, and 2017 was $629 thousand, $575 thousand, and $369 thousand, respectively.

Accrued Expenses

Accrued Expenses	12 Months Ended
	Dec. 31, 2019
Payables and Accruals [Abstract]
Accrued Expenses	5. Accrued Expenses Accrued expenses consist of the following: December 31, (in thousands) 2019 2018 Clinical services $ 5,247 $ 3,003 Employee compensation 1,910 1,786 Preclinical services 1,147 1,247 Professional services 991 745 Manufacturing services 586 1,164 Accrued vacation 489 363 Payroll taxes and benefits 284 349 Other consulting services 192 106 Total $ 10,846 $ 8,763

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2019
Related Party Transactions [Abstract]
Related Party Transactions	6. Related Party Transactions Collaborations with Precigen/ PGEN During the year ended December 31, 2018, the Company and PGEN entered into an Exclusive License Agreement (Note 7). During the year ended December 31, 2018, the Company issued an aggregate of 11,415 shares of Series 1 preferred stock to Precigen, the holder of all of the outstanding shares of the Company’s Series 1 preferred stock, as monthly dividend payments. The Company recorded such shares of Series 1 preferred stock at a fair value of $18.9 million, which is a component of temporary equity and recorded a loss on the change of the derivative liabilities in the amount of $1.3 million. See Notes 3 and 13 for additional discussion regarding the accounting for and valuation of these derivative financial instruments. During the years ended December 31, 2019, 2018, and 2017, the Company expensed $3.0 million, $8.1 million, and $21.4 million, respectively, for services performed by Precigen. As of December 31, 2019, and 2018, the Company recorded $0.1 million and $1.9 million, respectively, in current liabilities on its balance sheet for amounts due to Precigen. Collaboration with PGEN and MD Anderson On January 13, 2015, the C T-cell non-viral During the year ending December 31, 2019, the Company did not make any payments to MD Anderson, and the total aggregate payments in connection with this agreement are $41.9 million. The net balance of cash resources on hand at MD Anderson available to offset expenses and future costs is $20.3 million, which is included in prepaid expenses and

Settlement of a Related Party R

Settlement of a Related Party Relationship	12 Months Ended
	Dec. 31, 2019
Related Party Transactions [Abstract]
Settlement of relatedparty relationship	7. Settlement of a Related Party Relationship Exclusive License Agreement with PGEN Therapeutics On October 5, 2018, the Company entered into the license agreement with PGEN. As between the Company and PGEN, the terms of the License Agreement replace and supersede the terms of: (a) that certain Exclusive Channel Partner Agreement by and between the Company and Precigen, dated January 6, 2011, as amended by the First Amendment to Exclusive Channel Partner Agreement effective September 13, 2011, the Second Amendment to the Exclusive Channel Partner Agreement effective March 27, 2015, and the Third Amendment to Exclusive Channel Partner Agreement effective June 29, 2016, which was subsequently assigned by Precigen to PGEN; (b) certain rights and obligations pursuant to that certain License and Collaboration Agreement effective March 27, 2015 between ZIOPHARM, Precigen and ARES TRADING Trading S.A., or Ares Trading, a subsidiary of Merck KGaA, or Merck, as assigned by Precigen to PGEN, or the Ares Trading Agreement; (c) that certain License Agreement between the Company, Precigen, and MD Anderson, with an effective date of January 13, 2015, or the MD Anderson License, which was subsequently assigned by Precigen and assumed by PGEN effective as of January 1, 2018; and (d) that certain Research and Development Agreement between the Company, Precigen and MD Anderson with an effective date of August 17, 2015, or the Research and Development Agreement, and any amendments or statements of work thereto. Pursuant to the terms of the License Agreement, PGEN has granted the Company exclusive, worldwide rights to research, develop and commercialize (i) products utilizing PGEN’s RheoSwitch® gene switch, or RTS®, for the treatment of cancer, referred to as IL-12 Products, (ii) CAR products directed to (A) CD19 for the treatment of cancer, referred to as CD19 Products, and (B) a second target for the treatment of cancer, subject to the rights of Ares Trading to pursue such target under the Ares Trading Agreement, and (iii) T-cell receptor, or TCR, products designed for neoantigens for the treatment of cancer. PGEN has also granted the Company an exclusive, worldwide, royalty-bearing, sub-licensable license for certain patents relating to the Sleeping Beauty The Company is solely responsible for all aspects of the research, development and commercialization of the exclusively licensed products for the treatment of cancer. The Company is required to use commercially reasonable efforts to develop and commercialize IL-12 two-year PGEN has also granted the Company an exclusive, worldwide, royalty-bearing, sub-licensable IL-12 IL-12 In consideration of the licenses and other rights granted by PGEN, we will pay PGEN an annual license fee of $100 thousand and we have agreed to reimburse PGEN for certain historical costs of the licensed programs up to $1.0 million, payable quarterly. The Company determined that the fair value of this program was $1.0 million and this was expensed in accordance with ASC 730, Research and Development during the year ended December 31, 2018. The Company recorded a liability for $0.1 million and $1.0 million for the years ended December 31, 2019 and 2018, respectively, and has included these amounts in a The agreement also calls for an annual license fee of $100 thousand as long as the agreement is effective. The Company will also make milestone payments totaling up to an additional $52.5 million for each exclusively licensed program upon the initiation of later stage clinical trials and upon the approval of exclusively licensed products in various jurisdictions. In addition, the Company will pay PGEN tiered royalties ranging from low-single IL-12 low-single mid-single The Company is responsible for all development costs associated with each of the licensed products, other than Gorilla IL-12 IL-12 PGEN will pay the Company royalties ranging from low-single mid-single In consideration of the Company entering into the License Agreement, Precigen forfeited and returned to the Company all shares of the Company’s Series 1 preferred stock held by or payable to Precigen as of the date of the License Agreement. In addition, PGEN is required to transfer all of Ziopharm’s rights and obligations under the Ares Trading Agreement to Precigen (or its’ affiliate). As a result, Ziopharm shall not be responsible for any remaining obligations under the Merck Agreement. Additionally, Precigen forfeited and returned to the Company all shares of the Company’s Series 1 preferred stock held by or payable to Precigen as of the date of the License Agreement. The Company determined that this transaction represented a capital transaction between related parties. The Company fair valued the preferred stock and the derivative liability on the date of the transaction, noting a total fair value of $163.3 million. The relinquishment of the Ziopharm’s obligation under the Ares Trading Agreement was also considered part of the overall capital transaction. The Company recognized an additional credit to accumulated deficit of $49.5 million as a result of the relief of the obligation under the Ares Trading Agreement (Note 7). The total amount of the settlement was $212.8 million. The Company incurred approximately $7.4 million of transaction advisory costs with third-party vendors, of which $5.4 million was considered a direct cost associated with the Series 1 preferred stock extinguishment and is also included as part of the consideration transferred. The remaining $2.0 million of transaction costs were recognized as an expense during the year ended December 31, 2018. The Company recognized a net credit to accumulated deficit of $207.3 million, calculated as the difference in the carrying value of the Series 1 preferred stock, derivative liability, and contract liability, and the consideration transferred of $5.4 million, in connection with the transaction. This amount is included in net income available to common shareholders in the calculation of earnings per share for the year ended December 31, 2018 (Note 3).

Leases

Leases	12 Months Ended
	Dec. 31, 2019
Leases, Operating [Abstract]
Leases	8. Leases Operating Leases The Company adopted FASB ASU No. 2016-02, Leases (Topic 842) non-lease The Company uses its estimated incremental borrowing rate, which is derived from information available at the lease commencement date, in determining the present value of lease payments. The Company’s incremental borrowing rate represents the rate of interest that it would have to pay to borrow over a similar term an amount equal to the lease payments in a similar economic environment. The Company considers publicly available data for instruments with similar terms and characteristics when determining its incremental borrowing rates. The adoption of Topic 842 resulted in recognition of approximately $1.6 million of right-of-use right-of-use In June 2012, the Company entered into a master lease for the Company’s corporate office On March 12, 2019, the Company entered into a lease agreement for office space in Houston. Under the terms of the First Houston Lease agreement, the Company leases approximately one thousand and thirty-eight square feet and is required to make rental payments at an average monthly rate of approximately $2.0 thousand through April 2021. On October 15, 2019, the Company entered into a lease agreement for additional office space in Houston. Under the terms of the Second Houston Lease, the Company leases approximately eight thousand four hundred and forty-three square feet and is initially required to make rental payments of approximately $17.0 thousand through February 2027, subject to an annual base rent increase of approximately 3.0% throughout the term. The components of lease expense were as follows: (in thousands) Year Ended Operating lease cost $ 772 Total lease cost $ 772 Weighted-average remaining lease term (years) 4.42 Weighted-average discount rate 8.00 % Cash paid for amounts included in the measurement of the lease liabilities were $0.7 million for the year-ended December 31, 2019. The Company recognized new operating lease assets obtained in exchange for operating lease liabilities of $1.2 million for the year-ended December 31, 2019. As of December 31, 2019, the maturities of the Company’s operating lease liabilities were as follows (in thousands): Maturity of Lease Liabilities Operating Leases 2020 $ 925 2021 701 2022 213 2023 220 2024 226 Thereafter 514 Total lease payments $ 2,799 Less: Imputed Interest and Adjustments (447 ) Present value of lease payments $ 2,352 Disclosures related to periods prior to adoption of the New Lease Standard Prior to the adoption of ASC 842, the Company recorded rent expense on a straight-line basis over the term of the lease under ASC 840. Total rent expense was approximately $0.7 million and $0.7 million for the years ended December 31, 2018 and 2017, respectively. For comparative purposes, the Company’s aggregate future minimum non-cancellable 2019 723 2020 736 2021 488 Future minimum lease payments, net $ 1,947

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	9. Commitments and Contingencies License Agreements Exclusive License Agreement with PGEN On October 5, 2018, the Company entered into an exclusive license agreement with PGEN. Refer to Note 7—Settlement of a Related Party Relationship for further details. License Agreement and Research and Development Agreements—The University of Texas MD Anderson Cancer Center On January 13, 2015, ZIOPHARM, together with Precigen, entered into the MD Anderson License with MD Anderson (which Precigen subsequently assigned to PGEN). Pursuant to the MD Anderson License, the Company, together with PGEN, holds an exclusive, worldwide license to certain technologies owned and licensed by MD Anderson including technologies relating to novel CAR T-cell non-viral On August 17, 2015, the Company Pursuant to the Research and Development Agreement, the Com pany On October 22, 2019, the Company entered into the 2019 Research and Development Agreement, or the 2019 Agreement, with The University of Texas M.D. Anderson Cancer Center, or MD Anderson, pursuant to which the parties agreed to collaborate with respect to the Company’s Sleeping Beauty non-viral The Company will own all intellectual property developed under the 2019 Agreement and will retain all rights to intellectual property for oncology products manufactured using non-viral Sleeping Beauty non-exclusive The Company has agreed, beginning on January 1, 2021, to reimburse MD Anderson up to a total of $20.0 million for development costs under the 2019 Agreement. In addition, the Company will pay MD Anderson royalties on net sales of its TCR products at rates in the low single digits. The Company is required to make performance-based payments upon the successful completion of clinical and regulatory benchmarks relating to its TCR products. The aggregate potential benchmark payments are $36.5 million, of which only $3.0 million will be due prior to the first marketing approval of the Company’s TCR products. The royalty rates and benchmark payments owed to MD Anderson may be reduced upon the occurrence of certain events. The Company also agreed that it will sell the Company’s TCR products to MD Anderson at preferential prices and will sell its TCR products in Texas exclusively to MD Anderson for a limited period of time following the first commercial sale of the Company’s TCR products. In connection with the execution of the 2019 Agreement, the Company issued MD Anderson a warrant to purchase 3,333,333 shares of common stock. Refer to Note 10 – Warrants During the year ended December 31, 2019, the Company made no payments to MD Anderson compared to $2.7 million during the year ended December 31, 2018. The decrease in cash paid to MD Anderson during the year ended December 31, 2019 as compared to the same period in the prior year is a result of the final quarterly payment being made to MD Anderson in January 2018 and the result of approved expenditures incurred by the Company being deducted from the existing prepaid expense. The net balance of cash resources on hand at MD Anderson available to offset expenses and future costs is $20.3 million, which is included in prepaid expenses and The term of the MD Anderson License expires on the last to occur of (a) the expiration of all patents licensed thereunder, or (b) the twentieth anniversary of the date of the MD Anderson License; provided, however, that following the expiration of the term of the MD Anderson License, the Company, together with PGEN, shall then have a fully-paid up, royalty free, perpetual, irrevocable and sublicensable license to use the licensed intellectual property thereunder. After ten years from the date of the MD Anderson License and subject to a 90-day non-exclusive case-by-case 180-day License Agreement with the National Cancer Institute On May 28, 2019, the Company entered into a patent license agreement, or the Patent License, with the National Cancer Institute, or the NCI. Pursuant to the Patent License, the Company holds an exclusive, worldwide license to certain intellectual property to develop and commercialize patient-derived (autologous), peripheral blood T-cell TP T-cell non-viral non-exclusive, Pursuant to the terms of the Patent License, the Company is required to pay the NCI a cash payment in the aggregate amount of $1.5 million payable in $0.5 million installments within sixty days, six-months, d Under the amendment to the patent license signed in January 2020, we agreed to pay the NCI a cash payment of $600,000 within sixty days of the amendment. acc rued expenses on the Company’s balance sheet. At December 31, 2019, the Company included a prepayment of $0.3 million related to the Patent License as prepaid expenses and other curre n The terms of the Patent License also require the Company to pay the NCI minimum annual royalties in the amount of $0.3 million, which amount will be reduced to $0.1 million once the aggregate minimum annual royalties paid by the Company equals $1.5 million. The first minimum annual royalty payment is payable on the date that is eighteen months following the date of the Patent License. The Company is also required to make performance-based payments upon successful completion of clinical and regulatory benchmarks relating to the licensed products. The aggregate potential benchmark payments are $4.3 million, of which aggregate payments of $3.0 million are due only after marketing approval in the United States or in Europe, Japan, Australia, China or India. The first benchmark payment of $0.1 million will be due upon the initiation of the Company’s first sponsored phase 1 clinical trial of a licensed product or licensed process in the field of use licensed under the Patent License. In addition, the Company is required to pay the NCI one-time mid-single The Patent License will expire upon expiration of the last patent contained in the licensed patent rights, unless terminated earlier. The NCI may terminate or modify the Patent License in the event of a material breach, including if the Company does not meet certain milestones by certain dates, or upon certain insolvency events that remain uncured following the date that is 90 days following written notice of such breach or insolvency event. The Company may terminate the Patent License, or any portion thereof, in the Company’s sole discretion at any time upon 60 days’ written notice to the NCI. In addition, the NCI has the right to: (i) require the Company to sublicense the rights to the product candidates covered by the Patent License upon certain conditions, including if the Company is not reasonably satisfying required health and safety needs and (ii) terminate or modify the Patent License, including if the Company is not satisfying requirements for public use as specified by federal regulations. Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute On January 10, 2017, the Company announced the signing of the CRADA with the NCI for the development of adoptive cell transfer, or ACT,-based immunotherapies genetically modified using the Sleeping Beauty non-viral Sleeping Beauty Exclusive Channel Partner Agreement with PGEN for the Cancer Programs From 2011 to 2018, the Company was party to various arrangements with Precigen (now PGEN) in which the Company used PGEN’s technology to research and develop cancer treatments in return for various future profit sharing and royalty arrangements. These agreements were modified or terminated by the License Agreement described in Note 7. Ares Trading License and Collaboration Agreement On March 27, 2015, the Company, together with Precigen (now PGEN), signed the Ares Trading Agreement, with Ares Trading S.A., a subsidiary of the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, through which the parties established a collaboration for the research and development and commercialization of certain products for the prophylactic, therapeutic, palliative or diagnostic use for cancer in humans. PGEN was entitled to receive $5.0 million from Ares Trading, payable in equal quarterly installments over two years for each identified product candidate, which will be used to fund discovery work. The Company was responsible for costs exceeding the quarterly installments and all other costs of the preclinical research and development. For the year ended December 31, 2019, the Company incurred no expense under the Ares Trading Agreement. For the year ended December 31, 2018, the Company has expensed $0.1 million under the Ares Trading Agreement, respectively. For the year ended December 31, 2017, the Company expensed $1.6 million under the Ares Trading agreement. Ares Trading paid a non-refundable Under the License Agreement, PGEN agreed to perform all future obligations of the Company under the Ares Trading Agreement other than certain payment obligations. Accordingly, the Company recognized the remaining deferred revenue as part of the settlement of related party relationships as described in Note 7. Patent and Technology License Agreement—The University of Texas MD Anderson Cancer Center and the Texas A&M University System On August 24, 2004, the Company entered into a patent and technology license agreement with MD Anderson and the Texas A&M University System, which the Company refers to, collectively, as the Licensors. Under this agreement, were granted an exclusive, worldwide license to rights (including rights to U.S. and foreign patent and patent applications and related improvements and know-how) The Company issued options to purchase 50,222 shares outside of its stock option plans following the successful completion of certain clinical milestones, of which 37,666 shares have vested. The remaining 12,556 shares vested upon enrollment of the first patient in a multi-center pivotal clinical trial i.e. Collaboration Agreement with Solasia Pharma K.K. On March 7, 2011, the Company entered into a License and Collaboration Agreement with Solasia which was amended on July 31, 2014 to include an exclusive worldwide license. Pursuant to the License and Collaboration Agreement, the Company granted Solasia an exclusive license to develop and commercialize darinaparsin in both intravenous and oral forms and related organic arsenic molecules, in all indications for human use As consideration for the license, the Company is eligible to receive from Solasia development- and sales-based milestones, a royalty on net sales of darinaparsin, once commercialized, and a percentage of any sublicense revenues generated by Solasia. Solasia will be responsible for all costs related to the development, manufacturing and commercialization of darinaparsin. The Company’s Licensors, as defined in the agreement, will receive a portion of all milestone and royalty payments made by Solasia to the Company in accordance with the terms of the license agreement with the Licensors.

Warrants

Warrants	12 Months Ended
	Dec. 31, 2019
Warrants Disclosure [Abstract]
Warrant	10. Warrants In connection with the Company’s November 2018 private placement which provided net proceeds of approximately $47.1 million, the Company issued warrants to purchase an aggregate of 18,939,394 shares of common stock which became exercisable six months after the closing of the private placement. The warrants have an exercise price of $3.01 per share and have a five-year term. The relative fair value of the warrants was estimated at $18.4 million using a Black-Scholes model with the following assumptions: expected volatility of 71%, risk free interest rate of 2.99%, expected life of five years and no dividends. The Company assessed whether the both the 2019 and 2018 warrants required accounting as derivatives. The Company determined that the warrants were (1) indexed to the Company’s own stock and (2) classified in stockholders’ equity in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 815, Derivatives and Hedging On July 26, 2019 and September 12, 2019, the Company entered into agreements with existing investors for the exercise of previously issued warrants to purchase common stock in a private placement. Pursuant to the terms of the agreements, investors exercised their 2018 warrants for an aggregate of 17,803,031 shares of common stock, at an exercise price of $3.01 per share. The warrants exercised were originally issued by the Company in a private placement that closed in November 2018 (Note 2). Proceeds from the warrant exercise, after deducting placement agent fees and other related expenses of $1.1 million were approximately $52.5 million. The Company issued participating investors new warrants to purchase up to 17,803,031 additional shares of common stock as an inducement for the warrant holders to exercise their 2018 warrants early. The 2019 warrants will become exercisable six months following the date of issuance, will expire on the fifth anniversary of the initial exercise date, and have an exercise price of $7.00. The 2019 warrants were valued using a Black-Scholes valuation model and resulted in a $60.8 million non-cash in On October 22, 2019, the Company entered into the 2019 Agreement

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Income Taxes	11. Income Taxes There is no provision for income taxes because the Company has incurred operating losses since inception. The reported amount of income tax expense for the years differs from the amount that would result from applying domestic federal statutory tax rates to pretax losses primarily because of the changes in the valuation allowance. Significant components of the Company’s deferred tax assets at December 31, 2019 and 2018 are as follows: December 31, (in thousands) 2019 2018 Deferred tax assets: Net operating loss carryforwards $ 124,115 $ 106,430 Start-up 30,480 33,977 Research and development credit carryforwards 35,130 33,684 Stock compensation 1,087 990 Capitalized acquisition costs 4,501 5,160 Lease liability 626 — Depreciation 176 132 Other 1,186 920 197,301 181,293 Less valuation allowance (196,696 ) (181,293 ) Total deferred tax assets 605 — Deferred tax liabilities: Right of use asset (605 ) — Total deferred tax liabilities $ (605 ) $ — Net deferred tax e $ — $ — Deferred income taxes reflect the net tax effects of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. At December 31, 2019, the Company has aggregate net operating loss carryforwards for federal tax purposes of approximately $470 million, of which $342 million is available to offset future federal taxable income to the extent permitted under the Internal Revenue Code, or IRC, expiring in varying amounts through 2039 and approximately $128 million can be carried forward indefinitely. The Company also has approximately $404 million of state net operating loss carryforwards available to offset future state taxable income, expiring at various dates through 2039. Additionally, the Company has approximately $35.0 million of research and development credits at December 31, 2019, expiring in varying amounts through 2039, which may be available to reduce future taxes. In March 2016, the FASB issued ASU No. 2016-09, 2016-09), 2016-09 2016-09, In May 2014, the FASB issued an accounting standard update which provides for new revenue recognition guidance, superseding nearly all prior revenue recognition guidance. The new revenue standard outlines a single comprehensive model for accounting for revenue from contracts with customers and requires more detailed revenue disclosures. The Company adopted the new revenue standard on January 1, 2018 and as a result of the adoption increased deferred revenue by $8.1 million and decreased retained earnings by the same amount. Previously the Company had recorded revenue of $15.9 million and had deferred revenue of $41.5 million at December 31, 2017. The increase in the deferred revenue represented the recapture of revenue that was previously recorded and taxed. There was no impact to tax as the increase to the deferred tax asset was fully offset by the Company’s full valuation allowance. Under the IRC Section 382, certain substantial changes in the Company’s ownership may limit the amount of net operating loss carryforwards that can be utilized in any one year to offset future taxable income. Section 382 of the IRC provides limits to which a corporation that has undergone a change in ownership (as defined) can utilize any net operating loss, or NOL, and general business tax credit carryforwards it may have. The Company commissioned an analysis to determine whether Section 382 could limit the use of its carryforwards in this manner. After completing the analysis, it was determined an ownership change had occurred in February 2007. As a result of this change, the Company’s NOL’s and general business tax credits from February 23, 2007 and prior would be completely limited under IRC Section 382. The deferred tax assets related to NOL’s and general business credits have been reduced by $11.2 million and $636 thousand, respectively, as a result of the change. The Company updated the IRC Section 382 analysis through December 31, 2018. There was no change in ownership at this time. The Company has provided a valuation allowance for the full amount of these net deferred tax assets, since it is more likely than not that these future benefits will not be realized. However, these deferred tax assets may be available to offset future income tax liabilities and expenses. The valuation allowance in Income taxes using the federal statutory income tax rate differ from the Company’s effective tax rate primarily due to non-deductible A reconciliation of income tax expense (benefit) at the statutory federal income tax rate and income taxes as reflected in the financial statements is as follows: Year Ended December 31, (in thousands) 2019 2018 2017 Federal income tax at statutory rates 21 % 21 % 34 % State income tax, net of federal tax benefit 3 % 4 % 4 % Non-cash -11 % 0 % 0 % Research and development credits 1 % 2 % 3 % Stock compensation 0 % -1 % -1 % Research and development true-up 0 % 0 % -7 % Officers compensation 0 % -1 % -2 % Other -1 % -2 % -3 % Federal rate change 0 % 3 % -124 % Change in valuation allowance -13 % -26 % 96 % Effective tax rate 0 % 0 % 0 % The Company adopted ASC740, “Accounting for Uncertain Tax Positions” on January 1, 2007. ASC 740 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements in accordance with FASB Statement No. 109, “Accounting for Income Taxes.” ASC 740 prescribes a recognition threshold and measurement of a tax position taken or expected to be taken in a tax return. The Company did not establish any additional reserves for uncertain tax liabilities upon adoption of ASC 740. There were no adjustments to its uncertain tax positions in the years ended December 31, 2019, 2018, and 2017. The Company has not recognized any interest and penalties in the statement of operations because of the Company’s net operating losses and tax credits that are available to be carried forward. When necessary, the Company will account for interest and penalties related to uncertain tax positions as part of its provision for federal and state income taxes. The Company does not expect the amounts of unrecognized benefits will change significantly within the next twelve months. The Company is currently open to audit under the statute of limitations by the Internal Revenue Service and state jurisdictions for the years ended December 31, 1999 through 2019. The Tax Cuts and Jobs Act, or the “Tax Act,” was enacted in December 2017. The act significantly changes US tax law by, among other things, lowering US corporate income tax rates, implementing a territorial tax system, and imposing a one-time

Preferred Stock and Stockholder

Preferred Stock and Stockholders' Equity (Deficit)	12 Months Ended
	Dec. 31, 2019
Equity [Abstract]
Preferred Stock	12. Preferred Stock and Stockholders’ Equity (Deficit) On April 26, 2006, the date of the Company’s annual stockholders meeting that year, the shareholders approved the adoption of an Amended and Restated Certificate of Incorporation pursuant to which the Company has 280,000,000 shares of authorized capital stock, of which 250,000,000 shares are designated as common stock (par value $0.001 per share), and 30,000,000 shares are designated as preferred stock (par value $0.001 per share). Common Stock February 2020 Public Offering On February 5, 2020, the Company entered into an underwriting agreement with Jefferies, as representative of the several underwriters named therein, relating to the issuance and sale of 27,826,086 shares of its common stock. The price to the public in the offering was $3.25 per share, and the underwriters agreed to purchase the shares from the Company pursuant to the underwriting agreement at a purchase price of $3.055 per share. Under the terms of the underwriting agreement, the Company also granted the underwriters an option, exercisable for 30 days, to purchase up to an additional 4,173,912 shares of common stock at a purchase price of $3.055 per share. The offering was made pursuant to the Company’s effective registration statement on Form S-3ASR ( No. 333-232283) At-the-Market During the year ended December 31, 2019, the Company sold an aggregate of 1,271,274 shares of its common stock. The offering was made pursuant to the Company’s effective registration statement on Form S-3ASR ( Fi le Also, subsequent to December 31, 2019, the Company sold an aggregate of 2,814,673 shares of our common stock. The offering was made pursuant to the Company’s effective registration statement on Form S-3ASR ( File November 2018 Private Placement and 2019 I n On November 11, 2018, the Company entered into a securities purchase agreement with certain institutional and accredited investors, pursuant to which the Company agreed to issue and sell to the Investors an aggregate of 18,939,394 immediately separable units, with each unit being composed of (i) one share of the Company’s common stock, par value $0.001 per share, and (ii) a warrant to purchase one share of common stock, at a price per unit of $2.64, for net proceeds of approximately $47.1 million. May 2017 Offering On May 11, 2017, the Company sold in an underwritten offering an aggregate of 9,708,738 shares of its common stock. The price to the investor in the offering was $5.15 per share, and the underwriters agreed to purchase the shares from the Company pursuant to the Company’s registration statement on Form S-3ASR No. 333-201826) Preferred Stock The Company’s Board of Directors are authorized to designate any series of Preferred Stock, to fix and determine the variations in relative rights, preferences, privileges and restrictions as between and among such series. On June 29, 2016, the Company entered into a s certain a greements these am endments On October 5, 2018, the Company and PGEN entered into the License Agreement to replace all existing agreements between the companies, which provides the Company with certain exclusive and non-exclusive

Derivative Financial Instrument

Derivative Financial Instruments	12 Months Ended
	Dec. 31, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Financial Instruments	13. Derivative Financial Instruments The Company determined that certain embedded features related to the Series 1 preferred stock were derivative financial instruments. The company values the embedded derivative financial instruments related to the Series 1 preferred stock as Level 3 financial liabilities (Note 3). On October 5, 2018, the Company entered into the License Agreement with PGEN. In partial consideration for the termination of the former agreements, the Company and PGEN agreed that Precigen would forfeit all outstanding shares of the Series 1 preferred stock held by Precigen, including any accrued dividends and related financial instruments. Thus, upon closing of the transaction, these derivative financial instruments were no longer outstanding (Note 7). The change in the derivative liability for the years ended December 31, 2019, 2018 and 2017 consists of the following: Fair Value Balance, December 31, 2016 $ 862 Dividends 267 Change in fair value 1,295 Balance, December 31, 2017 $ 2,424 Dividends 223 Change in fair value (158 ) Settlement of a related party relationship (2,489 ) Balance, December 31, 2018 $ — Dividends — Change in fair value — Balance, December 31, 2019 $ — The fair value of the Series 1 preferred stock dividends was estimated using a probability-weighted approach and a Monte Carlo simulation model. The fair value of the embedded derivatives was estimated using the “with” and “without” method where the preferred stock was first valued with all of its features (“with” scenario) and then without derivatives subject to the valuation analysis (“without” scenario). The fair value of the derivatives was then estimated as the difference between the fair value of the preferred stock in the “with” scenario and the preferred stock in the “without” scenario. The model also takes into account, management estimates of clinical success/failure based upon market studies and probability of potential conversion and liquidation events. If these estimates were different, the valuations would change, and that change could be material. Inputs to the models included the following: December 31, 2018 Risk-free interest rate 2.50 - 3.13% Expected dividend rate 0 Expected volatility 77.6 - 82.4% Preferred stock conversion limit - percentage of outstanding common stock 19.90% Preferred conversion floor price $1.00

Stock Option Plan

Stock Option Plan	12 Months Ended
	Dec. 31, 2019
Text Block [Abstract]
Stock Options And Restricted Stock Awards Text Block [Text Block]	14. Stock Option Plan The Company adopted the 2012 Equity Incentive Plan, or the “2012 Plan,” in May 2012. Including subsequent increases, the Company ha d As of December 31, 2019 the Company had outstanding options to its employees to purchase up to 4,550,071 shares of the Company’s common stock, to its directors to purchase up to 1,282,808 shares of the Company’s common stock, as well as options to consultants in connection with services rendered to purchase up to 10,000 shares of the Company’s common stock. Stock options to employees generally vest ratably in either quarterly or two Proceeds from the option exercises during the years ended December 31, 2019, 2018, and 2017 amounted to $1.2 million, $0.2 million and $0.1 million respectively. The intrinsic value of these options amounted to $1.1 million, $0.1 million and $0.2 million for years ended December 31, 2019, 2018 and 2017, respectively. Transactions under the 2012 Plan for the years ending December 31, 2019, 2018, and 2017 were as follows: (in thousands, except share and per share data) Number of Weighted- Weighted- Aggregate Outstanding, December 31, 2016 3,465,335 $ 5.07 Granted 688,800 5.27 Exercised (180,000 ) 3.67 Cancelled (122,000 ) 6.64 Outstanding, December 31, 2017 3,852,135 5.12 Granted 1,744,950 2.35 Exercised (104,167 ) 2.30 Cancelled (215,833 ) 5.72 Outstanding, December 31, 2018 5,277,085 4.24 Granted 2,880,691 3.40 Exercised (581,105 ) 3.30 Cancelled (1,733,792 ) 4.21 Outstanding, December 31, 2019 5,842,879 $ 3.21 8.07 $ 7,482 Options exercisable, December 31, 2019 2,765,357 $ 4.39 6.70 $ 3,603 Options exercisable, December 31, 2018 3,099,935 $ 5.15 4.93 $ 88 Options available for future grant at December 31, 2019 2,503,508 In September 2017, the Company granted 500,000 inducement opt ion s On July 22, 2019, August 19, 2019, and November 21, 2019, the Company granted 400,000, 65,000, and 65,000 shares of its common stock, with exercise prices of $5.60, $5.18, and $4.59, respectively. The options vest ratably, over four years, commencing with one quarter on the first anniversary of the grant date and then quarterly thereafter. The options have a contractual term of ten years. These options were granted outside of the 2012 P At December 31, 2019, total unrecognized compensation costs related to non-vested Restricted Stock In January 2019, the Company issued 947,108 shares of restricted stock to its employees, which vest ratably in annual installments over three years, commencing on the first anniversary of the grant date. In September 2019, the Company issued 15,000 shares of restricted stock to its employees, which vest ratably in annual installments over four years, commencing with one-quarter non-employee one-year non-employee one-year non-employee one-year In January 2019, one of the Company’s executives received 446,428 shares of restricted stock in lieu of their annual cash bonus. The shares were immediately vested. In the year ended December 31, 2019, the Company repurchased 225,339 shares at average prices ranging from $2.24 to 4.72 to cover payroll taxes. In the year ended December 31, 2018, the Company repurchased 514,349 shares at average prices ranging from $1.70 to 4.41 to cover payroll taxes. In the year ended December 31, 2017, the Company repurchased 394,269 shares at average prices ranging from $4.14 to $7.12 to cover payroll taxes. A summary of the status of restricted stock as of December 31, 2019, 2018 and 2017 is as follows: Number of Weighted-Average Non-vested, 1,680,492 $ 7.49 Granted 907,032 4.14 Vested (778,965 ) 7.66 Cancelled — — Non-vested, 1,808,559 5.74 Granted 150,321 1.87 Vested (1,005,377 ) 6.62 Cancelled (271,433 ) 5.00 Non-vested, 682,070 3.47 Granted 1,519,766 2.44 Vested (1,187,601 ) 2.82 Cancelled (74,599 ) 3.41 Non-vested, 939,636 $ 2.93 As of December 31, 2019, there was $2.7 million of total unrecognized stock-based compensation expense related to non-vested

Employee Benefit Plan

Employee Benefit Plan	12 Months Ended
	Dec. 31, 2019
Postemployment Benefits [Abstract]
Employee Benefit Plan	15. Employee Benefit Plan The Company sponsors a qualified 401(k) retirement plan under which employees are allowed to contribute certain percentages of their pay, up to the maximum allowed under Section 401(k) of the IIRC. The Company may make contributions to this plan at its discretion. The Company contributed approximately $404 thousand, $329 thousand, and $90 thousand to this plan during the years ended December 31, 2019, 2018, and 2017, respectively.

Joint Venture

Joint Venture	12 Months Ended
	Dec. 31, 2019
Equity Method Investments and Joint Ventures [Abstract]
Joint Venture	16. Joint Venture On December 18, 2018, the Company entered into a Framework Agreement with TriArm Therapeutics, Ltd., or TriArm, whereby the parties will launch Eden BioCell, Ltd., or Eden BioCell, to lead clinical development and commercialization of certain Sleeping Beauty-generated CAR-T On January 3, 2019, Eden BioCell was incorporated in Hong Kong as a private company. Eden BioCell, the Company and TriArm entered into a Share Subscription Agreement on January 23, 2019, where the Company and TriArm agreed to contribute certain intellectual property, services and cash (only with respect to TriArm) to Eden BioCell to subscribe for a certain number of newly issued ordinary shares in the share capital of Eden BioCell. On the closing date, upon the issuance and subscription of the shares, in respect of the aforementioned consideration, 10,000,000 ordinary shares were issued to the Company and 10,000,000 ordinary shares were issued to TriArm. The closing of the transaction occurred on July 5, 2019. The Framework Agreement and Share Subscription Agreements were each respectively amended to be effective as of this date. Upon consummation of the joint venture, Eden BioCell and the Company also entered into a license agreement, pursuant to which the Company licensed the rights to Eden BioCell for third-generation Sleeping Beauty CAR-T As of July 5, 2019, as a result of the design and purpose of Eden BioCell, the Company determined that Eden BioCell was considered a variable interest entity, or VIE, and concluded that it is not the primary beneficiary of the VIE as it did not have the power to direct the activities of the VIE that most significantly impact its performance. Rather, the Company accounts for the equity interest in Eden BioCell under the equity method of accounting as it has the ability to exercise significant influence over the operations of Eden BioCell. The Company determined that Eden BioCell was not a customer and therefore, accounted for the transaction as the transfer of nonfinancial assets to be recognized at their fair value on the contribution date. The fair value of the intellectual property contributed to Eden BioCell had a de minimis value due to the early stage of the technology and the likelihood of clinical success. Due to the de minimis fair value of the intellectual property contributed, the Company did not record a gain or loss on this transaction and recognized a value of $0 for the equity-method investment.

Selected Quarterly Information

Selected Quarterly Information (Unaudited)	12 Months Ended
	Dec. 31, 2019
Quarterly Financial Information Disclosure [Abstract]
Selected Quarterly Information (Unaudited)	17. Selected Quarterly Information (Unaudited) (in thousands, except per share amounts) Year Ended December 31, 2019 First Second Third Fourth Revenue $ — $ — $ — $ — Total operating expenses 13,621 14,753 13,448 16,036 Loss from operations (13,621 ) (14,753 ) (13,448 ) (16,036 ) Non-cash — — (60,751 ) — Net income (loss) applicable to common shareholders (13,434 ) (14,620 ) (73,996 ) (15,746 ) Net income (loss) per share, basic $ (0.08 ) $ (0.09 ) $ (0.43 ) $ (0.09 ) Net income (loss) per share, diluted $ (0.08 ) $ (0.09 ) $ (0.43 ) $ (0.09 ) Year Ended December 31, 2018 First Second Third Fourth Revenue $ 146 $ — $ — $ — Total operating expenses 16,342 12,378 12,570 12,762 Loss from operations (16,196 ) (12,378 ) (12,570 ) (12,762 ) Preferred stock dividends (5,120 ) (5,462 ) (6,074 ) (342 ) Settlement of a related party relationship — — — 207,361 Net income (loss) applicable to common shareholders (21,140 ) (17,493 ) (18,659 ) 194,538 Net income (loss) per share, basic $ (0.15 ) $ (0.12 ) $ (0.13 ) $ 1.29 Net income (loss) per share, diluted $ (0.15 ) $ (0.12 ) $ (0.13 ) $ 1.29

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America or U.S. GAAP.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Although the Company regularly assesses these estimates, actual results could differ from those estimates. Changes in estimates are recorded in the period in which they become known. The Company’s most significant estimates and judgments used in the preparation of the financial statements are: • Clinical trial expenses; • Collaboration agreements; • Fair value measurements of stock-based compensation and Series 1 preferred stock (and related dividends); and • Income taxes.
Subsequent Events	Subsequent Events The Company evaluated all events and transactions that occurred after the balance sheet date through the date of this filing. Except as disclosed below, the Company did not have any material subsequent events that impacted its financial statements or disclosures. February 2020 Public Offering On February 5, 2020, the Company entered into an underwriting agreement with Jefferies, as representative of the several underwriters named therein, relating to the issuance and sale of 27,826,086 shares of its common stock. The net proceeds from the offering were approximately $85.0 million after deducting underwriting discounts and offering expenses paid by the Company (see Note 2). At-the-Market Subsequent to the balance sheet date, the Company sold an aggregate of 2,814,673 shares of its common stock. The offering was made pursuant to the Company’s effective registration statement on Form S-3ASR Amendment - License Agreement with the National Cancer Institute On January 8, 2020, we amended the Patent License to expand the TCR library licensed from the NCI to include additional TCRs reactive to mutated KRAS and TP53 neoantigens. Under the amendment to the patent license, we agreed to pay the NCI a cash payment of $600,000 within sixty days of the amendment.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash equivalents consist primarily of demand deposit accounts and deposits in short-term U.S. treasury money market mutual funds. Cash equivalents are stated at cost, which approximates fair market value. The following table provides a reconciliation of cash, cash equivalents, and restricted cash within the statement of financial position that sum to the total of the same such amounts shown in the statement of cash flows. December 31, (in thousands) 2019 2018 2017 Cash and cash equivalents $ 79,741 $ 61,729 $ 70,946 Restricted cash included in prepaid expenses and other current assets — — 388 Total cash, cash equivalents, and restricted cash shown in the statement of cash flows $ 79,741 $ 61,729 $ 71,334
Concentrations of Credit Risk	Concentrations of Credit Risk Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company maintains cash accounts in commercial banks, which may, at times, exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on cash and cash equivalents.
Property and Equipment	Property and Equipment Property and equipment are recorded at cost. Expenditures for maintenance and repairs are charged to expense while the costs of significant improvements are capitalized. Depreciation is provided using the straight-line method over the following estimated useful lives of the related assets, which is between three and five years. Upon retirement or sale, the cost of the assets disposed of and the related accumulated depreciation are eliminated from the balance sheets and related gains or losses are reflected in the statements of operations.
Long-Lived Assets	Long-Lived Assets The Company reviews the carrying values of its long-lived assets for possible impairment whenever events or changes in circumstances indicate that the carrying amounts of the assets may not be recoverable. Any long-lived assets held for disposal are reported at the lower of their carrying amounts or fair values less costs to sell.
Operating Segments	Operating Segments Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, the Company’s Chief Executive Officer, in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment and does not track expenses on a program-by-program
Warrants	Warrants The Company assesses whether warrants issued require accounting as derivatives. The Company determined that the warrants were (1) indexed to the Company’s own stock and (2) classified in stockholders’ equity in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 815, Derivatives and Hedging
Fair Value Measurements	Fair Value Measurements The Company has certain financial assets and liabilities recorded at fair value which have been classified as Level 1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements. • Level 1—Quoted prices in active markets for identical assets or liabilities. • Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. • Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Assets and liabilities measured at fair value on a recurring basis as of December 31, 2019 and 2018 are as follows: ($ in thousands) Fair Value Measurements at Reporting Date Using Description Balance as of Quoted Prices in Significant Other Significant Cash equivalents $ 68,031 $ 68,031 $ — $ — ($ in thousands) Fair Value Measurements at Reporting Date Using Description Balance as of Quoted Prices in Significant Other Significant Cash equivalents $ 24,437 $ 24,437 $ — $ — The cash equivalents represent demand deposit accounts and deposits in a short-term United States treasury money market mutual fund quoted in an active market and classified as a Level 1 asset.
Revenue Recognition from Collaboration Agreements	Revenue Recognition from Collaboration Agreements The Company adopted Accounting Standards Codification, or ASC Topic 606, Revenue from Contracts with Customers, The Company primarily generates revenue through collaboration arrangements with strategic partners for the development and commercialization of product candidates. Commencing January 1, 2018, the Company recognized revenue in accordance with ASC 606 which replaced ASC 605, Multiple Element Arrangements The Company recognizes collaboration revenue under certain of the Company’s license or collaboration agreements that are within the scope of ASC 606. The Company’s contracts with customers typically include promises related to licenses to intellectual property, research and development services and options to purchase additional goods and/or services. If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, up-front non-refundable, up-front The terms of the Company’s arrangements with customers typically include the payment of one or more of the following: (i) non-refundable, up-front catch-up The Company allocates the transaction price to each performance obligation identified in the contract on a relative standalone selling price basis. However, certain components of variable consideration are allocated specifically to one or more particular performance obligations in a contact to the extent both of the following criteria are met: (i) the terms of the payment relate specifically to the efforts to satisfy the performance obligation or transfer the distinct good or service and (ii) allocating the variable amount of consideration entirely to the performance obligation or the distinct good or service is consistent with the allocation objective of the standard whereby the amount allocated depicts the amount of consideration to which the entity expects to be entitled in exchange for transferring the promised goods or services. The Company develops assumptions that require judgment to determine the standalone selling price for each performance obligation identified in each contract. The key assumptions utilized in determining the standalone selling price for each performance obligation may include forecasted revenues, development timelines, estimated research and development costs, discount rates, likelihood of exercise and probabilities of technical and regulatory success. Revenue is recognized based on the amount of the transaction price that is allocated to each respective performance obligation when or as the performance obligation is satisfied by transferring a promised good and/or service to the customer. For performance obligations that are satisfied over time, the Company recognizes revenue by measuring the progress toward complete satisfaction of the performance obligation using a single method of measuring progress which depicts the performance in transferring control of the associated goods and/or services to the customer. The Company uses input methods to measure the progress toward the complete satisfaction of performance obligations satisfied over time. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. Any such adjustments are recorded on a cumulative catch-up T received in 2015 a former w e r e were There were d 340-40, Other Assets and Deferred Costs: Contracts with Customers The Company d id re-evaluate Impact of Topic 606 Adoption As a result of adopting ASC 606, the Company recorded an $8.1 million adjustment to the opening balance of accumulated deficit in the first quarter of 2018 as a result of the treatment of the up-front 605-25 ($ in thousands) Impact of Topic 606 Adoption Description As reported under Adjustments Balances without Contract liability, current portion $ 622 $ (5,767 ) $ 6,389 Contract liability, net of current portion $ 49,037 $ 13,898 $ 35,139 Accumulated deficit $ (720,573 ) $ (8,131 ) $ (712,442 ) ($ in thousands) Impact of Topic 606 Adoption Description As reported under Adjustments Balances without Collaboration revenue $ 146 $ (4,732 ) $ 4,878 Net loss $ (53,117 ) $ (4,732 ) $ (48,385 ) Net income (loss) applicable to common shareholders $ 137,246 $ (4,732 ) $ 141,978 Net income (loss) per share - basic $ 0.96 $ (0.03 ) $ 0.99 Net income (loss) per share - diluted $ 0.96 $ (0.03 ) $ 0.99 ($ in thousands) Impact of Topic 606 Adoption Description As reported under Adjustments Balances without Net loss $ (53,117 ) $ (4,732 ) $ (48,385 ) Changes in contract liability $ — $ — $ — The most significant change above relates to the Company’s collaboration revenue, which to date has been exclusively generated from its collaboration arrangement with Ares Trading and PGEN Therap eutic s , a wholly owned subsidiary of Precigen I nc., or P recigen , w hich was known as I nt rexon C orporation up-front
Research and Development Costs	Research and Development Costs Research and development expenditures are charged to the statement of operations as incurred. Such costs include proprietary research and development activities, purchased research and development, and expenses associated with research and development contracts, whether performed by the Company or contracted with independent third parties.
Income Taxes	Income Taxes Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences of temporary differences between the financial statement carrying amounts and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which the temporary differences are expected to be recovered or settled. The Company evaluates the realizability of its deferred tax assets and establishes a valuation allowance when it is more likely than not that all or a portion of deferred tax assets will not be realized. The Company accounts for uncertain tax positions using a “more-likely-than-not”
Accounting for Stock-Based Compensation	Accounting for Stock-Based Compensation Stock-based compensation cost is measured at the grant date, based on the estimated fair value of the award, and is recognized as expense over the employee’s requisite service period. Stock-based compensation expense is based on the number of awards ultimately expected to vest and is therefore reduced for an estimate of the awards that are expected to be forfeited prior to vesting. Consistent with prior years, the Company uses the Black-Scholes option pricing model which requires estimates of the expected term option holders will retain their options before exercising them and the estimated volatility of the Company’s common stock price over the expected term. The Company recognizes the full impact of its share-based employee payment plans in the statements of operations for each of the years ended December 31, 2019, 2018, and 2017 and did not capitalize any such costs on the balance sheets. The Company recognized $4.0 million, $3.0 million, and $2.5 million of compensation expense related to stock options during the years ended December 31, 2019, 2018, and 2017, respectively. In the years ended December 31, 2019, 2018, and 2017, the Company recognized $2.3 million, $4.5 million, and $6.0 million of compensation expense, respectively, related to restricted stock (Note 14). The total compensation expense relating to vesting of stock options and restricted stock awards for the years ended December 31, 2019, 2018, and 2017 was $6.3 million, $7.5 million, and $8.5 million, respectively. The following table presents share-based compensation expense included in the Company’s Statements of Operations: Year ended December 31, (in thousands) 2019 2018 2017 Research and development $ 1,461 $ 1,683 $ 2,401 General and administrative 4,880 5,851 6,053 Share based employee compensation expense before tax $ 6,341 $ 7,534 $ 8,454 Income tax benefit — — — Net share based employee compensation expense $ 6,341 $ 7,534 $ 8,454 The fair value of each stock option is estimated at the date of grant using the Black-Scholes option pricing model. The estimated weighted-average fair value of stock options granted to employees in 2019, 2018, and 2017 was approximately $2.47, $1.64, and $3.94 per share, respectively. Assumptions regarding volatility, expected term, dividend yield and risk-free interest rate are required for the Black-Scholes model. The volatility assumption is based on the Company’s historical experience. The risk-free interest rate is based on a U.S. treasury note with a maturity similar to the option award’s expected life. The expected life represents the average period of time that options granted are expected to be outstanding. The Company calculated expected term using the simplified method described in SEC Staff Accounting Bulletin, or SAB, No. 107 and No. 110 as it continues to meet the requirements promulgated in SAB No. 110. The assumptions for volatility, expected life, dividend yield and risk-free interest rate are presented in the table below: 2019 2018 2017 Weighted average risk-free interest rate 1.39 - 2.53% 2.55 - 3.06% 1.85 - 2.27% Expected life in years 5.75 - 6.25 6 6 Expected volatility 71.39 - 85.00% 80.75 - 84.71% 80.31 - 81.03% Expected dividend yield 0 0 0
Net Income (Loss) Per Share	Net Income ( ) Basic net loss per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding for the period. Diluted earnings (loss) per share is computed using the weighted-average number of common shares outstanding during the period, plus the dilutive effect of outstanding options and warrants, using the treasury stock method and the average market price of the Company’s common stock during the applicable period. For the Year Ended December 31, in thousands, except share and per share data 2019 2018 2017 Basic Net loss $ (117,796 ) $ (53,117 ) $ (54,323 ) Preferred stock dividends — (16,998 ) (18,938 ) Settlement of a related party relationship — 207,361 — Net income / (loss) applicable to common shareholders $ (117,796 ) $ 137,246 $ (73,261 ) Weighted-average common shares outstanding 167,952,114 143,508,674 136,938,264 Earnings per share, basic $ (0.70 ) $ 0.96 $ (0.53 ) Diluted Net Loss $ (117,796 ) $ (53,117 ) $ (54,323 ) Preferred stock dividends — (16,998 ) (18,938 ) Precigen license transaction — 207,361 — Net income / (loss) applicable to common shareholders $ (117,796 ) $ 137,246 $ (73,261 ) Weighted-average common shares outstanding 167,952,114 143,508,674 136,938,264 Effect of dilutive securities Stock options — 201,362 — Unvested restricted common stock — 124 — Warrants — — — Dilutive potential common shares — 201,486 — Shares used in calculating diluted earnings per share 167,952,114 143,710,160 136,938,264 Earnings per share, diluted $ (0.70 ) $ 0.96 $ (0.53 ) Certain shares related to some of the Company’s outstanding common stock options, unvested restricted stock, preferred stock, and warrants have not been included in the computation of diluted net earnings (loss) per share for the years ended December 31, 2019, 2018 and 2017 as the result would be antidilutive. Such potential common shares at December 31, 2019, 2018, and 2017 consist of the following: December 31, 2019 2018 2017 Stock options 6,872,879 5,075,723 4,352,135 Unvested restricted stock 939,636 681,946 1,808,559 Preferred stock — — 34,134,524 Warrants 22,272,727 18,939,394 — 30,085,242 24,697,063 40,295,218 During the year ended December 31, 2018, the Company and PGEN, entered into a License Agreement to replace all existing agreements between the companies that provides the Company with certain exclusive and non-exclusive
New Accounting Pronouncements	New Accounting Pronouncements In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement 2018-03. In June 2018, the FASB issued ASU No. 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting 2018-07. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) right-of-use No. 2016-02, non-lease Leases In May 2017, the FASB issued ASU No. 2017-09, Compensation—Stock Compensation Scope of Modification Accounting 2017-09, 2017-09

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Assets and Liabilities Measured at Fair Value on Recurring Basis	Assets and liabilities measured at fair value on a recurring basis as of December 31, 2019 and 2018 are as follows: ($ in thousands) Fair Value Measurements at Reporting Date Using Description Balance as of Quoted Prices in Significant Other Significant Cash equivalents $ 68,031 $ 68,031 $ — $ — ($ in thousands) Fair Value Measurements at Reporting Date Using Description Balance as of Quoted Prices in Significant Other Significant Cash equivalents $ 24,437 $ 24,437 $ — $ —
Impact of Topic 606 Adoption on Financial Statements	Impact of Topic 606 Adoption As a result of adopting ASC 606, the Company recorded an $8.1 million adjustment to the opening balance of accumulated deficit in the first quarter of 2018 as a result of the treatment of the up-front 605-25 ($ in thousands) Impact of Topic 606 Adoption Description As reported under Adjustments Balances without Contract liability, current portion $ 622 $ (5,767 ) $ 6,389 Contract liability, net of current portion $ 49,037 $ 13,898 $ 35,139 Accumulated deficit $ (720,573 ) $ (8,131 ) $ (712,442 ) ($ in thousands) Impact of Topic 606 Adoption Description As reported under Adjustments Balances without Collaboration revenue $ 146 $ (4,732 ) $ 4,878 Net loss $ (53,117 ) $ (4,732 ) $ (48,385 ) Net income (loss) applicable to common shareholders $ 137,246 $ (4,732 ) $ 141,978 Net income (loss) per share - basic $ 0.96 $ (0.03 ) $ 0.99 Net income (loss) per share - diluted $ 0.96 $ (0.03 ) $ 0.99 ($ in thousands) Impact of Topic 606 Adoption Description As reported under Adjustments Balances without Net loss $ (53,117 ) $ (4,732 ) $ (48,385 ) Changes in contract liability $ — $ — $ —
Share-Based Compensation Expense Included in Statements of Operations	The following table presents share-based compensation expense included in the Company’s Statements of Operations: Year ended December 31, (in thousands) 2019 2018 2017 Research and development $ 1,461 $ 1,683 $ 2,401 General and administrative 4,880 5,851 6,053 Share based employee compensation expense before tax $ 6,341 $ 7,534 $ 8,454 Income tax benefit — — — Net share based employee compensation expense $ 6,341 $ 7,534 $ 8,454
Assumptions for Volatility, Expected life, Dividend Yield and Risk-free Interest Rate	The assumptions for volatility, expected life, dividend yield and risk-free interest rate are presented in the table below: 2019 2018 2017 Weighted average risk-free interest rate 1.39 - 2.53% 2.55 - 3.06% 1.85 - 2.27% Expected life in years 5.75 - 6.25 6 6 Expected volatility 71.39 - 85.00% 80.75 - 84.71% 80.31 - 81.03% Expected dividend yield 0 0 0
Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method	Net Income ( ) Basic net loss per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding for the period. Diluted earnings (loss) per share is computed using the weighted-average number of common shares outstanding during the period, plus the dilutive effect of outstanding options and warrants, using the treasury stock method and the average market price of the Company’s common stock during the applicable period. For the Year Ended December 31, in thousands, except share and per share data 2019 2018 2017 Basic Net loss $ (117,796 ) $ (53,117 ) $ (54,323 ) Preferred stock dividends — (16,998 ) (18,938 ) Settlement of a related party relationship — 207,361 — Net income / (loss) applicable to common shareholders $ (117,796 ) $ 137,246 $ (73,261 ) Weighted-average common shares outstanding 167,952,114 143,508,674 136,938,264 Earnings per share, basic $ (0.70 ) $ 0.96 $ (0.53 ) Diluted Net Loss $ (117,796 ) $ (53,117 ) $ (54,323 ) Preferred stock dividends — (16,998 ) (18,938 ) Precigen license transaction — 207,361 — Net income / (loss) applicable to common shareholders $ (117,796 ) $ 137,246 $ (73,261 ) Weighted-average common shares outstanding 167,952,114 143,508,674 136,938,264 Effect of dilutive securities Stock options — 201,362 — Unvested restricted common stock — 124 — Warrants — — — Dilutive potential common shares — 201,486 — Shares used in calculating diluted earnings per share 167,952,114 143,710,160 136,938,264 Earnings per share, diluted $ (0.70 ) $ 0.96 $ (0.53 )
Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash	The following table provides a reconciliation of cash, cash equivalents, and restricted cash within the statement of financial position that sum to the total of the same such amounts shown in the statement of cash flows. December 31, (in thousands) 2019 2018 2017 Cash and cash equivalents $ 79,741 $ 61,729 $ 70,946 Restricted cash included in prepaid expenses and other current assets — — 388 Total cash, cash equivalents, and restricted cash shown in the statement of cash flows $ 79,741 $ 61,729 $ 71,334

Property and Equipment, net (Ta

Property and Equipment, net (Tables)	12 Months Ended
	Dec. 31, 2019
Property, Plant and Equipment [Abstract]
Component of Property and Equipment, Net	Property and equipment, net, consists of the following: December 31, (in thousands) 2019 2018 Office and computer equipment $ 1,436 $ 1,249 Software 1,030 1,030 Leasehold improvements 1,892 1,839 Research and development equipment 1,195 1,182 Capital in-process 389 — 5,942 5,300 Less: accumulated depreciation (4,832 ) (4,203 ) Property and equipment, net $ 1,110 $ 1,097

Accrued Expenses (Tables)

Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2019
Payables and Accruals [Abstract]
Component of Accrued Expenses	Accrued expenses consist of the following: December 31, (in thousands) 2019 2018 Clinical services $ 5,247 $ 3,003 Employee compensation 1,910 1,786 Preclinical services 1,147 1,247 Professional services 991 745 Manufacturing services 586 1,164 Accrued vacation 489 363 Payroll taxes and benefits 284 349 Other consulting services 192 106 Total $ 10,846 $ 8,763

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2019
Leases, Operating [Abstract]
Components of Lease Expense	The components of lease expense were as follows: (in thousands) Year Ended Operating lease cost $ 772 Total lease cost $ 772 Weighted-average remaining lease term (years) 4.42 Weighted-average discount rate 8.00 %
Lessee, Operating Lease, Liability, Maturity	As of December 31, 2019, the maturities of the Company’s operating lease liabilities were as follows (in thousands): Maturity of Lease Liabilities Operating Leases 2020 $ 925 2021 701 2022 213 2023 220 2024 226 Thereafter 514 Total lease payments $ 2,799 Less: Imputed Interest and Adjustments (447 ) Present value of lease payments $ 2,352
Future Net Minimum Lease Payments under Operating Leases	For comparative purposes, the Company’s aggregate future minimum non-cancellable 2019 723 2020 736 2021 488 Future minimum lease payments, net $ 1,947

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Significant Component of Deferred Tax Assets	Significant components of the Company’s deferred tax assets at December 31, 2019 and 2018 are as follows: December 31, (in thousands) 2019 2018 Deferred tax assets: Net operating loss carryforwards $ 124,115 $ 106,430 Start-up 30,480 33,977 Research and development credit carryforwards 35,130 33,684 Stock compensation 1,087 990 Capitalized acquisition costs 4,501 5,160 Lease liability 626 — Depreciation 176 132 Other 1,186 920 197,301 181,293 Less valuation allowance (196,696 ) (181,293 ) Total deferred tax assets 605 — Deferred tax liabilities: Right of use asset (605 ) — Total deferred tax liabilities $ (605 ) $ — Net deferred tax e $ — $ —
Reconciliation of Income Tax Expense (Benefit)	A reconciliation of income tax expense (benefit) at the statutory federal income tax rate and income taxes as reflected in the financial statements is as follows: Year Ended December 31, (in thousands) 2019 2018 2017 Federal income tax at statutory rates 21 % 21 % 34 % State income tax, net of federal tax benefit 3 % 4 % 4 % Non-cash -11 % 0 % 0 % Research and development credits 1 % 2 % 3 % Stock compensation 0 % -1 % -1 % Research and development true-up 0 % 0 % -7 % Officers compensation 0 % -1 % -2 % Other -1 % -2 % -3 % Federal rate change 0 % 3 % -124 % Change in valuation allowance -13 % -26 % 96 % Effective tax rate 0 % 0 % 0 %

Derivative Financial Instrume_2

Derivative Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2019
Change in Derivative Liability	The change in the derivative liability for the years ended December 31, 2019, 2018 and 2017 consists of the following: Fair Value Balance, December 31, 2016 $ 862 Dividends 267 Change in fair value 1,295 Balance, December 31, 2017 $ 2,424 Dividends 223 Change in fair value (158 ) Settlement of a related party relationship (2,489 ) Balance, December 31, 2018 $ — Dividends — Change in fair value — Balance, December 31, 2019 $ —
Series 1 Preferred Stock
Fair Value Assumptions Used in Probability Weighted Approach and Monte Carlo Simulation Model	The fair value of the Series 1 preferred stock dividends was estimated using a probability-weighted approach and a Monte Carlo simulation model. The fair value of the embedded derivatives was estimated using the “with” and “without” method where the preferred stock was first valued with all of its features (“with” scenario) and then without derivatives subject to the valuation analysis (“without” scenario). The fair value of the derivatives was then estimated as the difference between the fair value of the preferred stock in the “with” scenario and the preferred stock in the “without” scenario. The model also takes into account, management estimates of clinical success/failure based upon market studies and probability of potential conversion and liquidation events. If these estimates were different, the valuations would change, and that change could be material. Inputs to the models included the following: December 31, 2018 Risk-free interest rate 2.50 - 3.13% Expected dividend rate 0 Expected volatility 77.6 - 82.4% Preferred stock conversion limit - percentage of outstanding common stock 19.90% Preferred conversion floor price $1.00

Stock Option Plans (Tables)

Stock Option Plans (Tables)	12 Months Ended
	Dec. 31, 2019
Text Block [Abstract]
Transaction under Stock Option Plan	Transactions under the 2012 Plan for the years ending December 31, 2019, 2018, and 2017 were as follows: (in thousands, except share and per share data) Number of Weighted- Weighted- Aggregate Outstanding, December 31, 2016 3,465,335 $ 5.07 Granted 688,800 5.27 Exercised (180,000 ) 3.67 Cancelled (122,000 ) 6.64 Outstanding, December 31, 2017 3,852,135 5.12 Granted 1,744,950 2.35 Exercised (104,167 ) 2.30 Cancelled (215,833 ) 5.72 Outstanding, December 31, 2018 5,277,085 4.24 Granted 2,880,691 3.40 Exercised (581,105 ) 3.30 Cancelled (1,733,792 ) 4.21 Outstanding, December 31, 2019 5,842,879 $ 3.21 8.07 $ 7,482 Options exercisable, December 31, 2019 2,765,357 $ 4.39 6.70 $ 3,603 Options exercisable, December 31, 2018 3,099,935 $ 5.15 4.93 $ 88 Options available for future grant at December 31, 2019 2,503,508
Summary of Non-Vested Restricted Stock	A summary of the status of restricted stock as of December 31, 2019, 2018 and 2017 is as follows: Number of Weighted-Average Non-vested, 1,680,492 $ 7.49 Granted 907,032 4.14 Vested (778,965 ) 7.66 Cancelled — — Non-vested, 1,808,559 5.74 Granted 150,321 1.87 Vested (1,005,377 ) 6.62 Cancelled (271,433 ) 5.00 Non-vested, 682,070 3.47 Granted 1,519,766 2.44 Vested (1,187,601 ) 2.82 Cancelled (74,599 ) 3.41 Non-vested, 939,636 $ 2.93

Selected Quarterly Informatio_2

Selected Quarterly Information (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2019
Quarterly Financial Information Disclosure [Abstract]
Selected Quarterly Information	Year Ended December 31, 2019 First Second Third Fourth Revenue $ — $ — $ — $ — Total operating expenses 13,621 14,753 13,448 16,036 Loss from operations (13,621 ) (14,753 ) (13,448 ) (16,036 ) Non-cash — — (60,751 ) — Net income (loss) applicable to common shareholders (13,434 ) (14,620 ) (73,996 ) (15,746 ) Net income (loss) per share, basic $ (0.08 ) $ (0.09 ) $ (0.43 ) $ (0.09 ) Net income (loss) per share, diluted $ (0.08 ) $ (0.09 ) $ (0.43 ) $ (0.09 ) Year Ended December 31, 2018 First Second Third Fourth Revenue $ 146 $ — $ — $ — Total operating expenses 16,342 12,378 12,570 12,762 Loss from operations (16,196 ) (12,378 ) (12,570 ) (12,762 ) Preferred stock dividends (5,120 ) (5,462 ) (6,074 ) (342 ) Settlement of a related party relationship — — — 207,361 Net income (loss) applicable to common shareholders (21,140 ) (17,493 ) (18,659 ) 194,538 Net income (loss) per share, basic $ (0.15 ) $ (0.12 ) $ (0.13 ) $ 1.29 Net income (loss) per share, diluted $ (0.15 ) $ (0.12 ) $ (0.13 ) $ 1.29

Organization - Additional Infor

Organization - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Feb. 29, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Proceeds from Issuance Initial Public Offering		$ 6,085
Cash and cash equivalents		$ 79,741	$ 61,729	$ 70,946
Subsequent Event [Member]
Proceeds from Issuance Initial Public Offering	$ 98,000

Financings - Additional Informa

Financings - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	Feb. 05, 2020	Sep. 12, 2019	Nov. 11, 2018	May 11, 2017	Sep. 30, 2019	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Apr. 26, 2006
Class of Stock [Line Items]
Stock issued during period				9,708,738		2,814,673
Issuance & sale of common stock in public offering price per share				$ 5.15
Sale of stock price per share				$ 4.893
Sale of stock consideration received on transaction				$ 47,300
Common stock, par value			$ 0.001			$ 0.001	$ 0.001		$ 0.001
Gross proceeds received						$ 6,085	$ 47,101	$ 47,270
Class of warrant or right, number of securities called by warrants or rights			18,939,394
Warrant Exercise Price per share			$ 2.64
Proceeds from private placement		$ 52,500
Non-cash inducement warrant expense					$ (60,751)	$ 60,751
Subsequent Event [Member]
Class of Stock [Line Items]
Stock issued during period	2,814,673
Gross proceeds received	$ 13,000
At The Market Offering [Member]
Class of Stock [Line Items]
Stock issued during period						1,271,274
Sale of stock consideration received on transaction						$ 6,100
At The Market Offering [Member] | Subsequent Event [Member]
Class of Stock [Line Items]
Sale of stock consideration received on transaction	$ 13,000
Private Placement [Member]
Class of Stock [Line Items]
Class of warrant or right, number of securities called by warrants or rights		17,803,031				18,939,394
Warrant Exercise Price per share		$ 3.01				$ 3.01
Placement agent fees and other expenses		$ 1,100
Private Placement [Member] | New Warrants [Member]
Class of Stock [Line Items]
Class of warrant or right, number of securities called by warrants or rights		17,803,031
Warrant Exercise Price per share		$ 7
Non-cash inducement warrant expense		$ 60,800				$ 60,800
Securities Purchase Agreement [Member]
Class of Stock [Line Items]
Stock issued during period			18,939,394
Common stock, par value			$ 0.001
par value per share			$ 2.64
Gross proceeds received			$ 47,100			$ 47,100
Underwriting Agreement [Member]
Class of Stock [Line Items]
Stock issued during period						2,814,673
Sale of stock consideration received on transaction						$ 13,000
Underwriting Agreement [Member] | Subsequent Event [Member]
Class of Stock [Line Items]
Stock issued during period	27,826,086
Issuance & sale of common stock in public offering price per share	$ 3.25
Sale of stock consideration received on transaction	$ 85,000
par value per share	$ 3.055
Underwriting Agreement [Member] | Maximum [Member] | Subsequent Event [Member]
Class of Stock [Line Items]
Stock issued during period	4,173,912

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)	Feb. 05, 2020	Jan. 08, 2020	Jan. 02, 2018	May 11, 2017	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Jan. 01, 2018
Summary Of Significant Accounting Policies [Line Items]
Stock based compensation expenses					$ 6,341,000	$ 7,534,000	$ 8,454,000
Weighted average fair value of stock option granted					$ 2.47	$ 1.64	$ 3.94
Accumulated deficit					$ (684,125,000)	$ (566,329,000)	$ (712,442,000)
Transaction Price					$ 57,500,000
Changes in contract liability						(146,000)	(6,389,000)
Issuance of Common Stock to Underwriters				9,708,738	2,814,673
Net Proceeds from Underwriting					$ 6,085,000	47,101,000	47,270,000
Number of common Stock Sold				9,708,738	2,814,673
Net Proceeds from Sales					$ 6,085,000	47,101,000	47,270,000
Underwriting Agreement with Jefferies [Member]
Summary Of Significant Accounting Policies [Line Items]
Issuance of Common Stock to Underwriters	27,826,086
Net Proceeds from Underwriting	$ 85,000,000
Number of common Stock Sold	27,826,086
Net Proceeds from Sales	$ 85,000,000
Underwriting Agreement [Member]
Summary Of Significant Accounting Policies [Line Items]
Issuance of Common Stock to Underwriters	2,814,673
Net Proceeds from Underwriting	$ 13,000,000
Number of common Stock Sold	2,814,673
Net Proceeds from Sales	$ 13,000,000
Difference between revenue guidance in effect before and after topic 606
Summary Of Significant Accounting Policies [Line Items]
Accumulated deficit								$ 8,100,000
Research and Development Services Contract Term					9 years
Changes in contract liability			$ 8,100,000
Stock Options
Summary Of Significant Accounting Policies [Line Items]
Stock based compensation expenses					$ 4,000,000	3,000,000	2,500,000
Restricted Stock
Summary Of Significant Accounting Policies [Line Items]
Stock based compensation expenses					2,300,000	4,500,000	6,000,000
Restricted Stock Units (RSUs) [Member]
Summary Of Significant Accounting Policies [Line Items]
Stock based compensation expenses					$ 6,300,000	7,500,000	8,500,000
Minimum [Member]
Summary Of Significant Accounting Policies [Line Items]
Property and equipment useful life					3 years
Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Property and equipment useful life					5 years
Subsequent Event
Summary Of Significant Accounting Policies [Line Items]
Issuance of Common Stock to Underwriters	2,814,673
Net Proceeds from Underwriting	$ 13,000,000
Number of common Stock Sold	2,814,673
Net Proceeds from Sales	$ 13,000,000
Subsequent Event | License Amendment Agreement
Summary Of Significant Accounting Policies [Line Items]
Expected cash payment payable		$ 600,000
Period for paying the estimated cash from the date of amendment		60 days
ASU 2014-09
Summary Of Significant Accounting Policies [Line Items]
Accumulated deficit							(720,573,000)
ASU 2014-09 | Difference between revenue guidance in effect before and after topic 606
Summary Of Significant Accounting Policies [Line Items]
Accumulated deficit							$ (8,131,000)
Changes in contract liability					$ 0	$ 0

Reconciliation of Cash, Cash Eq

Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents	$ 79,741	$ 61,729	$ 70,946
Restricted cash included in prepaid expenses and other current assets			388
Total cash, cash equivalents, and restricted cash shown in the statement of cash flows	$ 79,741	$ 61,729	$ 71,334	$ 81,441

Assets and Liabilities Measured

Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - Fair Value, Measurements, Recurring - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	$ 68,031	$ 24,437
Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	$ 68,031	$ 24,437

Impact of Topic 606 Adoption on

Impact of Topic 606 Adoption on Financial Statements (Detail) - USD ($) $ / shares in Units, $ in Thousands	Jan. 02, 2018	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Jan. 01, 2018
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Contract liability, current portion												$ 6,389
Contract liability, net of current portion												35,139
Accumulated deficit		$ (684,125)				$ (566,329)				$ (684,125)	$ (566,329)	(712,442)
Collaboration revenue									$ 146		146	6,389
Net loss		$ (15,746)	$ (73,996)	$ (14,620)	$ (13,434)	$ 194,538	$ (18,659)	$ (17,493)	$ (21,140)	(117,796)	(53,117)	(54,323)
Net income (loss) applicable to common shareholders										$ (117,796)	$ 137,246	$ (73,261)
Net income (loss) per share—basic		$ (0.09)	$ (0.43)	$ (0.09)	$ (0.08)	$ 1.29	$ (0.13)	$ (0.12)	$ (0.15)	$ (0.70)	$ 0.96	$ (0.53)
Net income (loss) per share—diluted		$ (0.09)	$ (0.43)	$ (0.09)	$ (0.08)	$ 1.29	$ (0.13)	$ (0.12)	$ (0.15)	$ (0.70)	$ 0.96	$ (0.53)
Net loss		$ (15,746)	$ (73,996)	$ (14,620)	$ (13,434)	$ 194,538	$ (18,659)	$ (17,493)	$ (21,140)	$ (117,796)	$ (53,117)	$ (54,323)
Changes in contract liability											(146)	(6,389)
ASU 2014-09
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Contract liability, current portion												622
Contract liability, net of current portion												49,037
Accumulated deficit												(720,573)
Difference between Revenue Guidance in Effect before and after Topic 606
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Accumulated deficit													$ 8,100
Changes in contract liability	$ 8,100
Difference between Revenue Guidance in Effect before and after Topic 606 | ASU 2014-09
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Contract liability, current portion												(5,767)
Contract liability, net of current portion												13,898
Accumulated deficit												$ (8,131)
Collaboration revenue											(4,732)
Net loss											(4,732)
Net income (loss) applicable to common shareholders											$ (4,732)
Net income (loss) per share—basic											$ (0.03)
Net income (loss) per share—diluted											$ (0.03)
Net loss											$ (4,732)
Changes in contract liability										$ 0	0
Calculated under Revenue Guidance in Effect before Topic 606 | ASU 2014-09
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Collaboration revenue											4,878
Net loss											(48,385)
Net income (loss) applicable to common shareholders											$ 141,978
Net income (loss) per share—basic											$ 0.99
Net income (loss) per share—diluted											$ 0.99
Net loss											$ (48,385)

Stock-Based Compensation Expens

Stock-Based Compensation Expense Included in Statement of Operations (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	$ 6,341	$ 7,534	$ 8,454
Net share based employee compensation expense	6,341	7,534	8,454
Research and Development Expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	1,461	1,683	2,401
General and Administrative Expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	$ 4,880	$ 5,851	$ 6,053

Fair Value of Stock Options Ass

Fair Value of Stock Options Assumptions Using Black-Scholes Option Valuation Model (Detail)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Risk-free interest rate, Minimum	1.39%	2.55%	1.85%
Risk-free interest rate, Maximum	2.53%	3.06%	2.27%
Expected life in years	5 years	6 years	6 years
Expected volatility, Minimum	71.39%	80.75%	80.31%
Expected volatility, Maximum	85.00%	84.71%	81.03%
Expected dividend yield	0.00%	0.00%	0.00%
Maximum [Member]
Expected life in years	6 years 3 months
Minimum [Member]
Expected life in years	5 years 9 months

Earning Per share Basic and Dil

Earning Per share Basic and Diluted (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Earnings Per Share, Basic [Abstract]
Net loss	$ (15,746)	$ (73,996)	$ (14,620)	$ (13,434)	$ 194,538	$ (18,659)	$ (17,493)	$ (21,140)	$ (117,796)	$ (53,117)	$ (54,323)
Preferred stock dividends					$ (342)	$ (6,074)	$ (5,462)	$ (5,120)		(16,998)	(18,938)
Settlement of a related party relationship										207,361
Net income (loss) applicable to common stockholders									$ (117,796)	$ 137,246	$ (73,261)
Weighted-average common shares outstanding									167,952,114	143,508,674	136,938,264
Earnings per share, basic	$ (0.09)	$ (0.43)	$ (0.09)	$ (0.08)	$ 1.29	$ (0.13)	$ (0.12)	$ (0.15)	$ (0.70)	$ 0.96	$ (0.53)
Earnings Per Share, Diluted [Abstract]
Net loss	$ (15,746)	$ (73,996)	$ (14,620)	$ (13,434)	$ 194,538	$ (18,659)	$ (17,493)	$ (21,140)	$ (117,796)	$ (53,117)	$ (54,323)
Preferred stock dividends					$ (342)	$ (6,074)	$ (5,462)	$ (5,120)		(16,998)	(18,938)
Precigen license transaction										207,361
Net income (loss) applicable to common stockholders									$ (117,796)	$ 137,246	$ (73,261)
Weighted-average common shares outstanding									167,952,114	143,508,674	136,938,264
Effect of dilutive securities
Stock options										201,362
Unvested restricted common stock										124
Dilutive potential common shares										201,486
Shares used in calculating diluted earnings per share									167,952,114	143,710,160	136,938,264
Earnings per share, diluted	$ (0.09)	$ (0.43)	$ (0.09)	$ (0.08)	$ 1.29	$ (0.13)	$ (0.12)	$ (0.15)	$ (0.70)	$ 0.96	$ (0.53)

Potential Dilutive Shares Exclu

Potential Dilutive Shares Excluded from Computation of Diluted Net Loss Per Share (Detail) - shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	30,085,242	24,697,063	40,295,218
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	22,272,727	18,939,394
Stock Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	6,872,879	5,075,723	4,352,135
Unvested Restricted Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	939,636	681,946	1,808,559
Series 1 Preferred Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount			34,134,524

Component of Property and Equip

Component of Property and Equipment, Net (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Property, Plant and Equipment [Line Items]
Property and equipment, Gross	$ 5,942	$ 5,300
Less: accumulated depreciation	(4,832)	(4,203)
Property and equipment, net	1,110	1,097
Office and computer equipment
Property, Plant and Equipment [Line Items]
Property and equipment, Gross	1,436	1,249
Software
Property, Plant and Equipment [Line Items]
Property and equipment, Gross	1,030	1,030
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property and equipment, Gross	1,892	1,839
Research and development equipment
Property, Plant and Equipment [Line Items]
Property and equipment, Gross	1,195	$ 1,182
Capital in-process
Property, Plant and Equipment [Line Items]
Property and equipment, Gross	$ 389

Property and Equipment, net - A

Property and Equipment, net - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Property, Plant and Equipment [Abstract]
Depreciation	$ 629	$ 575	$ 369

Component of Accrued Expenses (

Component of Accrued Expenses (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Payables and Accruals [Abstract]
Clinical consulting services	$ 5,247	$ 3,003
Employee compensation	1,910	1,786
Preclinical services	1,147	1,247
Manufacturing services	586	1,164
Professional services	991	745
Accrued vacation	489	363
Payroll taxes and benefits	284	349
Other consulting services	192	106
Total	$ 10,846	$ 8,763

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - USD ($)	Jun. 29, 2016	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2015
Related Party Transaction [Line Items]
Change in fair value of derivative liability		$ 0	$ 158,000	$ (1,295,000)
Amounts expensed for services incurred		57,858,000	54,052,000	59,882,000
Research and development expense		38,331,000	34,134,000	45,084,000
MD Anderson License and the Research and Development Agreement Member [Member]
Related Party Transaction [Line Items]
Cash resources on hand		20,300,000
Series 1 Preferred Stock
Related Party Transaction [Line Items]
Temporary equity, fair value		18,900,000
Change in fair value of derivative liability		1,300
License Agreement | M.D. Anderson Cancer Center
Related Party Transaction [Line Items]
Issuance of common stock in licensing agreement (in shares)					11,722,163
Research and development expense					$ 67,300,000
Cooperative Research and Development Agreement | M.D. Anderson Cancer Center
Related Party Transaction [Line Items]
Research and development service agreement aggregate payments		41,900,000
Intrexon Corporation/Precigen
Related Party Transaction [Line Items]
Amounts expensed for services incurred		3,000,000	8,100,000	$ 21,400,000
Amount due to related party, current		100,000	$ 1,900,000
Research and development expense		$ 1,000,000
Intrexon Corporation/Precigen | Series 1 Preferred Stock
Related Party Transaction [Line Items]
Issuance of common stock in licensing agreement (in shares)	100,000	11,415

Settlement of a Related Party_2

Settlement of a Related Party Relationship - Additional Information (Detail) - USD ($) $ in Thousands	Oct. 05, 2018	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Transaction advisory costs recognized as expense				$ 2,000
Related party transaction, amounts of transaction		$ 207,361
Research and development expense			$ 38,331	34,134	$ 45,084
Preferred Stock Redemption Discount				207,361
RelatedParty Liability		$ 1,000	100	$ 1,000
Gorilla IL-12 Products
Percentage of development cost shared by other party	80.00%
Percentage of operating profit shared by other party	80.00%
Precigen
Annual Licensing fee			100
Intrexon Corporation/Precigen
Annual Licensing fee	$ 100,000
Reimbursement of historical costs	1,000
Preferred stock, contract liability, derivative liability	163,300
Increase in accumulated deficit	49,500
Related party transaction, amounts of transaction	212,800
Research and development expense			$ 1,000
Additional milestone payment for exclusively licensed program to be paid	52,500
Maximum Royalty payable	$ 100,000
Percentage of sublicensing income	20.00%
Royalty payment to be received	$ 50,000
Intrexon Corporation/Precigen | Gorilla IL-12 Products
Percentage of development cost shared by other party	20.00%
Percentage of operating profit shared by other party	20.00%
Third Party Vendor
Transaction advisory costs recognized as expense	$ 7,400
Series 1 Preferred Stock [Member]
Transaction advisory costs recognized as expense	5,400
Series 1 Preferred Stock [Member] | Intrexon Corporation/Precigen
Consideration transferred	207,300
Preferred Stock Redemption Discount	$ 5,400

Lease expense (Detail)

Lease expense (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2019USD ($)
Operating lease cost	$ 772
Total lease cost	$ 772
Weighted-average remaining lease term (years)	4 years 5 months 1 day
Weighted-average discount rate	8.00%

Operating lease liabilities (De

Operating lease liabilities (Detail) $ in Thousands	Dec. 31, 2019USD ($)
2020	$ 925
2021	701
2022	213
2023	220
2024	226
Thereafter	514
Total lease payments	2,799
Less: Imputed Interest and Adjustments	(447)
Present value of lease payments	$ 2,352

Future minimum current and non-

Future minimum current and non-current lease liabilities (Detail) $ in Thousands	Dec. 31, 2018USD ($)
2019	$ 723
2020	736
2021	488
Future minimum lease payments, net	$ 1,947

Leases - Additional Information

Leases - Additional Information (Details)	Oct. 15, 2019USD ($)ft²	Mar. 12, 2019USD ($)ft²	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Jan. 01, 2019USD ($)	Jan. 30, 2018USD ($)ft²
Land Subject to Ground Leases | ft²		1,038
Lessee Operating Lease Monthly Average Rental Payment		$ 2,000
Operating Lease, Payments			$ 700,000
Total rent expense				$ 700,000	$ 700,000
Operating Lease, Right-of-Use Asset			2,272,000
Operating Lease, Liability			2,352,000
Recognisition in exchange of Operating Lease Liabilities			1,200,000
Boston, MA
Security Deposit			$ 100,000	$ 100,000
Sublease term amendment			Aug. 31, 2021
Operating lease expiration month and year			2016-08
Houston, TX
Land Subject to Ground Leases | ft²	8,443
Operating Lease Area | ft²							210
Operating Leases Future Minimum Monthly Payment Due Through Year 2021	$ 17,000						$ 1,000
Annual Base Rent	3.00%
Adjustments for New Accounting Pronouncement [Member]
Operating Lease, Right-of-Use Asset						$ 1,600,000
Operating Lease, Liability						$ 1,600,000

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) - USD ($)

May 28, 2019

May 11, 2017

Jan. 13, 2015

Jul. 31, 2015

Dec. 31, 2019

Dec. 31, 2018

Dec. 31, 2017

Jan. 01, 2021

Nov. 28, 2020

Oct. 22, 2019

Feb. 19, 2019

Nov. 11, 2018

Oct. 05, 2018

May 31, 2016

Dec. 31, 2014

Aug. 24, 2004

Accrued Payments

Research and development expense

$ 38,331,000

$ 34,134,000

$ 45,084,000

Cash balance

79,741,000

61,729,000

$ 70,946,000

Agreement commencement date

2015-05

Number of Warrants

18,939,394

MD Anderson License and the Research and Development Agreement Member [Member]

Accrued Payments

Research and development service agreement aggregate quarterly payments

0

2,700,000

Reimbursement of historical costs

$ 20,000,000

Accrued Payments

3,000,000

Number of Warrants

3,333,333

Aggregate potential benchmark payments

$ 36,500,000

CRADA Agreement [Member]

Accrued Payments

Obligations due under contract

$ 5,000,000

Quarterly payments under contract

$ 2,500,000

License Agreement with the National Cancer Institute [Member]

Accrued Payments

Expected cash payment payable per installments

$ 500,000

The University of Texas MD Anderson Cancer Center and The Texas A & M University System

Accrued Payments

Milestone maximum payment

$ 4,500,000

Options to purchase common stock

50,222

Shares vested

37,666

The University of Texas MD Anderson Cancer Center and The Texas A & M University System | Research and Development Expense

Accrued Payments

Issuance of common stock in a license agreement

$ 87,000

The University of Texas MD Anderson Cancer Center and The Texas A & M University System | Upon enrollment of the first patient in a multi-center pivotal clinical trial

Accrued Payments

Shares vested

12,556

Solasia

Accrued Payments

Upfront payment received

$ 5,000,000

Milestone payment received

$ 1,000,000

Milestone Payments Payable

$ 1,000,000

ARES Trading License

Accrued Payments

Research and development expense

$ 100,000

$ 1,600,000

License Agreement with the National Cancer Institute [Member]

Accrued Payments

Reimbursement of historical costs

46,000

Expected Cash Payment Payable

1,500,000

500,000

Minimum Royalties Amount Payable

$ 300,000

Description Of First Annual Royalty Payable

The first minimum annual royalty payment is payable on the date that is eighteen months following the date of the Patent License.

Description Of First Benchmark Payable

The first benchmark payment of $0.1 million will be due upon the initiation of the Company’s first sponsored phase 1 clinical trial of a licensed product or licensed process in the field of use licensed under the Patent License.

Description Of option To terminate Agreement

The NCI may terminate or modify the Patent License in the event of a material breach, including if the Company does not meet certain milestones by certain dates, or upon certain insolvency events that remain uncured following the date that is 90 days following written notice of such breach or insolvency event.

Agreement termination, notice period

60 days

payments under the Patent License

$ 600,000

1,000,000

License Agreement with the National Cancer Institute [Member] | Performance Based Payments Member [Member]

Accrued Payments

Aggregate Benchmark Payments Payable

4,300,000

License Agreement with the National Cancer Institute [Member] | One Time Benchmark Payments [Member]

Accrued Payments

Potential Benchmark Payments Payable

12,000,000

License Agreement with the National Cancer Institute [Member] | Scenario, Forecast [Member]

Accrued Payments

Expected Cash Payment Payable

$ 1,500,000

Minimum Royalties Amount Payable

$ 100,000

License Agreement with the National Cancer Institute [Member] | Post Marketing Approval [Member] | Performance Based Payments Member [Member]

Accrued Payments

Aggregate Benchmark Payments Payable

3,000,000

License Agreement with the National Cancer Institute [Member] | licensed products [Member] | One Time Benchmark Payments [Member]

Accrued Payments

Maximum Sales Revenue On Which Benchmark Payments Payable

$ 1,000,000,000

Prepaid Expenses and Other Current Assets

Accrued Payments

Prepaid Patent

300,000

Prepaid Expenses and Other Current Assets | MD Anderson License

Accrued Payments

Cash balance

20,300,000

Intrexon Corporation

Accrued Payments

Licensing fee

$ 115,000,000

Research and development expense

$ 1,000,000

Upfront payment received

$ 57,500,000

Percentage of upfront fee Payable

50.00%

Reimbursement of historical costs

$ 1,000,000

Minimum [Member] | MD Anderson License and the Research and Development Agreement Member [Member]

Accrued Payments

Research and development expense

$ 15,000,000

Maximum [Member] | MD Anderson License and the Research and Development Agreement Member [Member]

Accrued Payments

Research and development expense

$ 20,000,000

Warrants - Additional Informati

Warrants - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	Sep. 12, 2019	Nov. 11, 2018	Sep. 30, 2019	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Number of securities into which the class of warrant converted		18,939,394
Warrant Exercise Per share		$ 2.64
Fair Value Assumptions Expected volatility Rate Maximum				85.00%	84.71%	81.03%
Fair Value Assumptions Risk Free Interest Rate Maximum				2.53%	3.06%	2.27%
Fair Value Assumptions Expected Term1				5 years	6 years	6 years
Net Proceeds from Underwriting				$ 6,085	$ 47,101	$ 47,270
Proceeds from private placement	$ 52,500
Non-cash inducement warrant expense			$ (60,751)	$ 60,751
MD Anderson Warrant [Member]
Number of securities into which the class of warrant converted				3,333,333
Warrant Exercise Per share				$ 0.001
Grant Date Fair Value of a warrant				$ 14,500
Warrant Expiry date				Dec. 31, 2026
Securities Purchase Agreement [Member]
Net Proceeds from Underwriting		$ 47,100		$ 47,100
Private Placement [Member]
Number of securities into which the class of warrant converted	17,803,031			18,939,394
Warrant Exercise Per share	$ 3.01			$ 3.01
Grant Date Fair Value of a warrant				$ 18,400
Fair Value Assumptions Expected volatility Rate Maximum				71.00%
Fair Value Assumptions Risk Free Interest Rate Maximum				2.99%
Placement agent fees and other expenses	$ 1,100
Private Placement [Member] | New Warrants [Member]
Number of securities into which the class of warrant converted	17,803,031
Warrant Exercise Per share	$ 7
Non-cash inducement warrant expense	$ 60,800			$ 60,800

Significant Component of Deferr

Significant Component of Deferred Tax Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Net operating loss carryforwards	$ 124,115	$ 106,430
Deferred tax assets:
Start-up and organizational costs	30,480	33,977
Research and development credit carryforwards	35,130	33,684
Stock compensation	1,087	990
Capitalized acquisition costs	4,501	5,160
Lease liability	626
Depreciation	176	132
Other	1,186	920
Deferred Tax Assets Gross	197,301	181,293
Less valuation allowance	(196,696)	(181,293)
Total deferred tax assets	605	0
Deferred tax liabilities:
Right of use asset	(605)	0
Total deferred tax liabilities	(605)	0
Net deferred taxes	$ 0	$ 0

Reconciliation of Income Tax Ex

Reconciliation of Income Tax Expense (Benefit) (Detail)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Federal income tax at statutory rates	21.00%	21.00%	34.00%
State income tax, net of federal tax benefit	3.00%	4.00%	4.00%
Non-cash inducement warrant expense	(11.00%)	0.00%	0.00%
Research and development credits	1.00%	2.00%	3.00%
Stock compensation	0.00%	(1.00%)	(1.00%)
Research and development true-up	0.00%	0.00%	(7.00%)
Officers compensation	0.00%	(1.00%)	(2.00%)
Other	(1.00%)	(2.00%)	(3.00%)
Federal rate change	0.00%	3.00%	(124.00%)
Change in valuation allowance	(13.00%)	(26.00%)	96.00%
Effective tax rate	0.00%	0.00%	0.00%

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	Jan. 02, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2013	Dec. 31, 2016
Income Taxes [Line Items]
Net operating loss carryforwards		$ 124,115	$ 106,430
Deferred tax assets operating loss carryforwards without expire date		128,000
Research and development credit carryforwards		$ 35,130	33,684
Net operating loss carryforwards, expiration date		2039
Accumulated excess tax benefit recognised as deferred tax asset		$ 605	0
Uncertain Tax Positions Adjustment		0	$ 0	$ 0
Increase (decrease) in deferred tax assets		$ 15,400
Effective income tax rate		21.00%	21.00%	34.00%
Increase (decrease) in deferred revenue			$ (146)	$ (6,389)
Revenues				15,900
Deferred revenue				$ 41,500
Difference between revenue guidance in effect before and after topic 606
Income Taxes [Line Items]
Increase (decrease) in deferred revenue	$ 8,100
ASU 2016-09
Income Taxes [Line Items]
Accumulated excess tax benefit recognised as deferred tax asset						$ 10,200
Accumulated Deficit | ASU 2016-09
Income Taxes [Line Items]
Cumulative-effect adjustment from adoption of ASU 2016-09						$ 122
Tax Cuts And Jobs Act of 2017
Income Taxes [Line Items]
Effective income tax rate		21.00%	35.00%
Change in tax rate in income tax expense benefit		$ 67,000
Research Tax Credit Carryforward
Income Taxes [Line Items]
Research and development credit carryforwards		35,000
Net Operating Loss Carryforwards
Income Taxes [Line Items]
Increase (decrease) in deferred tax assets					$ (11,200)
General Business Credits
Income Taxes [Line Items]
Increase (decrease) in deferred tax assets					$ (636)
Domestic Tax Authority
Income Taxes [Line Items]
Net operating loss carryforwards		$ 470,000
Net operating loss carryforwards, expiration date		2039
Federal and State
Income Taxes [Line Items]
Deferred tax assets operating loss carryforwards with expire date		$ 342,000
State and Local Jurisdiction
Income Taxes [Line Items]
Net operating loss carryforwards		$ 404,000

Preferred Stock and Stockhold_2

Preferred Stock and Stockholders' Equity (Deficit) - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	Feb. 05, 2020	Nov. 11, 2018	May 11, 2017	Jun. 29, 2016	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Apr. 26, 2006
Equity [Line Items]
Shares of authorized capital stock								280,000,000
Common stock, shares authorized					250,000,000	250,000,000		250,000,000
Initial Public Offering of Common Stock		$ 0.001			$ 0.001	$ 0.001		$ 0.001
Preferred stock, shares authorized					30,000,000	30,000,000		30,000,000
Issuance of Common Stock to Underwriters			9,708,738		2,814,673
Net Proceeds from Underwriting					$ 6,085	$ 47,101	$ 47,270
Sale of stock consideration received on transaction			$ 47,300
Issuance & sale of common stock in public offering price per share			$ 5.15
Number of securities into which the class of warrant converted		18,939,394
Warrant Exercise Price per share		$ 2.64
Warrant exercise, net of commissions and expenses		$ 47,100			$ 52,499
Subsequent Event
Equity [Line Items]
Issuance of Common Stock to Underwriters	2,814,673
Net Proceeds from Underwriting	$ 13,000
At The Market Offering [Member]
Equity [Line Items]
Issuance of Common Stock to Underwriters					1,271,274
Sale of stock consideration received on transaction					$ 6,100
At The Market Offering [Member] | Subsequent Event
Equity [Line Items]
Sale of stock consideration received on transaction	$ 13,000
Series 1 Preferred Stock
Equity [Line Items]
Preferred stock, stated value					$ 1,200	$ 1,200
Intrexon Corporation/Precigen | Series 1 Preferred Stock
Equity [Line Items]
Issuance of common stock in licensing agreement (in shares)				100,000	11,415
Preferred stock, stated value				$ 1,200
Underwriting Agreement with Jefferies [Member] | Subsequent Event
Equity [Line Items]
Initial Public Offering of Common Stock	$ 3.25
Issuance of Common Stock to Underwriters	27,826,086
Underwriters Purchase Price	$ 3.055
Number of Days Option Exerciable	30 days
Net Proceeds from Underwriting	$ 85,000
Underwriting Agreement with Jefferies [Member] | Maximum [Member] | Subsequent Event
Equity [Line Items]
Issuance of Common Stock to Underwriters	4,173,912
Underwriting Agreement [Member]
Equity [Line Items]
Issuance of Common Stock to Underwriters					2,814,673
Sale of stock consideration received on transaction					$ 13,000
Underwriting Agreement [Member] | Subsequent Event
Equity [Line Items]
Issuance of Common Stock to Underwriters	27,826,086
Underwriters Purchase Price	$ 3.055
Sale of stock consideration received on transaction	$ 85,000
Issuance & sale of common stock in public offering price per share	$ 3.25
Underwriting Agreement [Member] | Maximum [Member] | Subsequent Event
Equity [Line Items]
Issuance of Common Stock to Underwriters	4,173,912

Change in Derivative Liability

Change in Derivative Liability (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Beginning Balance	$ 0	$ 2,424	$ 862
Dividends	0	223	267
Change in fair value	0	(158)	1,295
Settlement of a related party relationship		(2,489)
Ending Balance	$ 0	$ 0	$ 2,424

Fair Value Assumptions Used in

Fair Value Assumptions Used in Probability Weighted Approach and Monte Carlo Simulation Model for Derivatives (Detail) - Series 1 Preferred Stock	12 Months Ended
	Dec. 31, 2018$ / shares
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Preferred stock conversion limit - percentage of outstanding common stock	19.90%
Preferred conversion floor price	$ 1
Measurement Input, Expected Dividend Rate [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Fair Value Assumptions of Preferred Stock	0.00%
Minimum [Member] | Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Fair Value Assumptions of Preferred Stock	2.50%
Minimum [Member] | Measurement Input, Price Volatility [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Fair Value Assumptions of Preferred Stock	77.60%
Maximum [Member] | Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Fair Value Assumptions of Preferred Stock	3.13%
Maximum [Member] | Measurement Input, Price Volatility [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Fair Value Assumptions of Preferred Stock	82.40%

Stock Option Activity Under Sto

Stock Option Activity Under Stock Option Plan (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Number of Shares
Beginning Balance	5,277,085	3,852,135	3,465,335
Granted	2,880,691	1,744,950	688,800
Exercised	(581,105)	(104,167)	(180,000)
Cancelled	(1,733,792)	(215,833)	(122,000)
Ending Balance	5,842,879	5,277,085	3,852,135
Options exercisable, at end of period	2,765,357	3,099,935
Options available for future grant	2,503,508
Weighted Average Exercise Price
Beginning Balance	$ 4.24	$ 5.12	$ 5.07
Granted	3.40	2.35	5.27
Exercised	3.30	2.30	3.67
Cancelled	4.21	5.72	6.64
Ending Balance	3.21	4.24	$ 5.12
Options exercisable, at end of period	$ 4.39	$ 5.15
Weighted Average Contractual Term (Years)
Outstanding, at end of period	8 years 25 days
Options exercisable, at end of period	6 years 8 months 12 days	4 years 11 months 4 days
Aggregate Intrinsic Value
Outstanding, at end of period	$ 7,482
Options exercisable, at end of period	$ 3,603	$ 88

Summary of Non-Vested Restricte

Summary of Non-Vested Restricted Stock (Detail) - Unvested Restricted Common Stock - $ / shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Number of Shares
Beginning Balance	682,070	1,808,559	1,680,492
Granted	1,519,766	150,321	907,032
Vested	(1,187,601)	(1,005,377)	(778,965)
Cancelled	(74,599)	(271,433)
Ending Balance	939,636	682,070	1,808,559
Weighted Average Grant Date Fair Value
Beginning Balance	$ 3.47	$ 5.74	$ 7.49
Granted	2.44	1.87	4.14
Vested	2.82	6.62	7.66
Cancelled	3.41	5
Ending Balance	$ 2.93	$ 3.47	$ 5.74

Stock Option Plan - Additional

Stock Option Plan - Additional information (Detail) - USD ($) $ / shares in Units, $ in Thousands	Nov. 21, 2019	Aug. 19, 2019	Jul. 22, 2019	Sep. 30, 2019	Jan. 31, 2019	Sep. 30, 2017	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for future issuance							5,842,879
Outstanding options issued							5,842,879	5,277,085	3,852,135	3,465,335
Proceeds from stock options exercised							$ 1,219	$ 240	$ 88
Total intrinsic value of options							$ 1,100	$ 100	$ 200
Stock options, granted							2,880,691	1,744,950	688,800
Stock options granted exercise price							$ 3.40	$ 2.35	$ 5.27
Options available for future grant							2,503,508
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Repurchase of shares of restricted common stock							225,339	514,349	394,269
restricted stock in lieu					446,428
Restricted Stock | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Repurchase of shares of restricted common stock, price per share							$ 4.72	$ 4.41	$ 7.12
Restricted Stock | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Repurchase of shares of restricted common stock, price per share							$ 2.24	$ 1.70	$ 4.14
Restricted Stock | Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based payment award granted					947,108			30,000	838,000
Restricted Stock | Non Employee Directors
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based payment award granted				15,000			111,230	120,321	69,032
Unvested Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation costs related to non-vested restricted stock outstanding							$ 9,000
Expected recognition period							1 year 9 months 10 days
Unvested Restricted Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected recognition period							1 year 3 months 14 days
Share-based payment award granted							1,519,766	150,321	907,032
Unrecognized stock-based compensation expense related to non-vested restricted stock arrangements							$ 2,700
the "2012 Plan"
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for future issuance							14,000,000
the "2012 Plan" | Employees | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding options issued							4,550,071
the "2012 Plan" | Director | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding options issued							1,282,808
the "2012 Plan" | Consultants | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding options issued							10,000
Outside 2012 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for future issuance							1,030,000
Outstanding options issued							1,030,000
Stock options, granted	65,000	65,000	400,000			500,000
Stock options granted exercise price	$ 4.59	$ 5.18	$ 5.60			$ 6.16
Share Based compensation arrangement by share based payment award options grants grant date fair value	$ 193	$ 231	$ 1,500			$ 2,200

Employee Benefit Plan - Additio

Employee Benefit Plan - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Retirement Benefits [Abstract]
Defined benefit plan contributions by employer	$ 404	$ 329	$ 90

Joint Venture - Additional Inf

Joint Venture - Additional Information (Detail) - USD ($) $ in Millions	Jul. 05, 2019	Dec. 31, 2019	Jan. 03, 2019	Dec. 31, 2018
Subsidiary or Equity Method Investee [Line Items]
Common stock, shares issued		181,803,320		161,066,136
Eden Bio Cell [Member]
Subsidiary or Equity Method Investee [Line Items]
Equity method investments		$ 0
Ziopharm [Member] | Eden Bio Cell [Member]
Subsidiary or Equity Method Investee [Line Items]
Equity interest in affilated entity	50.00%
Tri Arm [Member] | Eden Bio Cell [Member]
Subsidiary or Equity Method Investee [Line Items]
Equity interest in affilated entity	50.00%
Tri Arm [Member] | License Agreement Terms [Member] | Eden Bio Cell [Member]
Subsidiary or Equity Method Investee [Line Items]
Milestone payment made	$ 10
Conditional milestone amount payable	$ 25
Share Subscription Agreement [Member] | Ziopharm [Member] | Eden Bio Cell [Member]
Subsidiary or Equity Method Investee [Line Items]
Common stock, shares issued			10,000,000
Share Subscription Agreement [Member] | Tri Arm [Member] | Eden Bio Cell [Member]
Subsidiary or Equity Method Investee [Line Items]
Common stock, shares issued			10,000,000

Selected Quarterly Informatio_3

Selected Quarterly Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Quarterly Financial Information Disclosure [Abstract]
Revenue								$ 146		$ 146	$ 6,389
Total operating expenses	$ 16,036	$ 13,448	$ 14,753	$ 13,621	$ 12,762	$ 12,570	$ 12,378	16,342
Loss from operations	(16,036)	(13,448)	(14,753)	(13,621)	(12,762)	(12,570)	(12,378)	(16,196)	$ (57,858)	(53,906)	(53,493)
Non-cash inducement warrant expense		(60,751)							60,751
Preferred stock dividends					(342)	(6,074)	(5,462)	(5,120)		(16,998)	(18,938)
Settlement of a related party relationship					207,361
Net income (loss) applicable to common shareholders	$ (15,746)	$ (73,996)	$ (14,620)	$ (13,434)	$ 194,538	$ (18,659)	$ (17,493)	$ (21,140)	$ (117,796)	$ (53,117)	$ (54,323)
Net income (loss) per share, basic	$ (0.09)	$ (0.43)	$ (0.09)	$ (0.08)	$ 1.29	$ (0.13)	$ (0.12)	$ (0.15)	$ (0.70)	$ 0.96	$ (0.53)
Net income (loss) per share, diluted	$ (0.09)	$ (0.43)	$ (0.09)	$ (0.08)	$ 1.29	$ (0.13)	$ (0.12)	$ (0.15)	$ (0.70)	$ 0.96	$ (0.53)